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ABSTRACT 
Pancreatic cancer remains a devastating disease and conventional chemotherapy shows 
modest efficacy because of drug resistance and systemic toxicity. The reprogramming of energy 
metabolism and oxidative stress are two hallmarks of cancer, and redox modulators have been 
developed as an attractive approach to treat cancer. At low or moderate levels, reactive oxygen 
species (ROS) serve as signaling molecules to mediate cellular functions; while at high levels, 
ROS induce oxidation of lipids, proteins, and DNA, ultimately leading to cell death. In this 
dissertation project, I aimed to identify novel redox modulators and provide a preclinical 
characterization of their mechanisms of action (MOAs) in pancreatic cancer cells. 
Through lead optimization of a previously studied quinazolinedione-based redox 
modulator, we identified QD394 with significant cytotoxicity in pancreatic cancer cells. Bru-seq 
technique and clustering analysis revealed remarkably similar post-treatment transcriptomic 
profiles between QD394 and napabucasin. Both compounds inhibited STAT3 phosphorylation, 
induced DNA damage, increased cellular ROS, and decreased the GSH/GSSG ratio. Moreover, 
QD394 caused an iron- and ROS-dependent, GPX4-mediated cell death, suggesting ferroptosis 
as a major mechanism. QD394 also decreased the expression of mitochondrial proteins, 
including LRPPRC and PNPT1 involved in mitochondrial RNA catabolic processes. A 
derivative QD394-Me was synthesized with improved plasma stability and reduced toxicity in 
mice compared to QD394. These results demonstrate that QD394 and QD394-Me represent 
 
 
 
 
 
 
 xv 
novel ROS-inducing drug-like compounds warranting further development for the treatment of 
pancreatic cancer. 
Mito-Chlor, a mitochondrial-targeting triphenylphosphonium derivative of the nitrogen 
mustard chlorambucil, was identified to inhibit transcription of the mitochondrial genome 
through Bru-seq analysis, which is similar to a new ROS inducer SQD1 featuring a 
styrylquinoline-5, 8-dione core. Both Mito-Chlor and SQD1 decreased the mRNA levels of 
mitochondrial genes. However, only Mito-Chlor reduced their protein expression, and interfered 
with mitochondria membrane potential and oxidative phosphorylation. Both compounds 
increased cellular and mitochondrial ROS and stimulated similar downstream signaling related to 
oxidative stress and AP-1 transcription factors. These results establish SQD1 and Mito-Chlor as 
novel mitochondrial transcription inhibitors and redox modulators that may be applied to study 
cancer cell death related to mitochondrial function and redox signaling. 
Finally, a medium-throughput phenotypic screen of 20,000 diverse drug-like compounds 
produced a quinolin-chlorobenzothioate, QCBT7, as a potent hit with submicromolar 
cytotoxicity in cancer cells. Its structure is similar to 8-quinolinethiol hydrochloride (8TQ), a 
proteasome inhibitor. Proteasome inhibitors have shown anticancer efficacy. As a more stable 
derivative of 8TQ, QCBT7 caused the accumulation of ubiquitylated proteins, indicating its 
proteasome inhibitory activity. Additionally, QCBT7 increased the expression of a set of genes 
(PFKFB4, CHOP, HMOX1, and SLC7A11) at both nascent RNA and protein levels, similar to 
the known proteasome inhibitors MG132 and ixazomib. We have also identified PFKFB4 as a 
potential biomarker of proteasome inhibitors that can be used to monitor treatment response. 
Together, this study discovers that QCBT7 induces proteasome inhibition, hypoxic response, 
endoplasmic reticulum stress, and glycolysis, leading to cell death. 
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In summary, the work as a whole provides a detailed characterization of redox 
modulators and their effects on cell death, mitochondria, or proteasome activity. We also identify 
novel ROS-related genes and pathways that could be beneficial for pancreatic cancer 
therapeutics. This thesis contributes to the overall understanding of ROS signaling in pancreatic 
cancer and the validity of ROS-modulating therapies. This collective work provides the 
foundation to improve the redox modulators discovered for testing in vivo. 
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CHAPTER I 
Introduction  
Reactive oxygen species (ROS) are partially reduced metabolites of oxygen with strong 
oxidizing capabilities that contribute to diseases related to cell metabolism, survival, and death. 
There are two main classes of ROS: free radicals and non-radicals. Free radicals include 
hydroxyl radical (HO•), nitric oxide (•NO), peroxynitrite (ONOO−), superoxide anion (O2•−), 
nitrogen dioxide (•NO2), peroxyl radicals (ROO•), and lipid peroxyl (LOO•). Non-radicals 
include hydrogen peroxide (H2O2), singlet oxygen (1O2), and lipid peroxide (LOOH). The most 
well-studied ROS are hydrogen peroxide (H2O2), superoxide anion (O2•−), and hydroxyl radical 
(HO•) 1. At low doses, ROS maintain cellular homeostasis as secondary signaling molecules, and, 
at high concentrations, ROS can induce severe oxidative damage in proteins, lipids, and DNA, 
earning their reputation as a double-edged sword 2–4.  
ROS signaling in mitochondria and endoplasmic reticulum 
ROS are generated via both non-enzymatic and enzymatic reactions. ROS generated as 
byproducts of oxidative phosphorylation and ATP production during electron transfer reactions 
in the mitochondria are the major source (Figure I-1). ATP generation depends on the 
mitochondrial respiratory chain in the inner mitochondrial membrane, which consists of five 
major protein complexes (complex I, II, III, IV, and V) 5. ATP is synthesized by F0F1-ATPase 
via the proton gradient across the membrane, and during this electron transfer, molecular oxygen 
accepts leaked electrons to form ROS 6. Complex I (NADH dehydrogenase subunits) and 
Notes: Part of the work has been published as Shergalis, A. G., Hu, S., Bankhead, A., 3rd & Neamati, N. 
Pharmacol. Ther. 107525 (2020). 
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complex III (ubiquinol-cytochrome C reductase complex subunits) are the major sites of electron 
leak in the mitochondrial respiratory chain 7,8. Furthermore, complex II (succinate 
dehydrogenase) also plays a role in ROS generation, and mutation or dysfunction of complex II 
can enhance ROS production 9. In addition to the mitochondria, ROS are also produced by 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidases and xanthine oxidase in the 
cytoplasm, and generated in the endoplasmic reticulum (ER), peroxisome, and other organelles 2. 
Although mitochondria hold the reputation as the primary ROS-inducing organelles of the cell, 
oxidative protein folding in the ER generates large quantities of ROS, and in fact, the ER lumen 
contains more ROS than mitochondria 10,11. The ER and mitochondria interact via a physical 
contact known as the mitochondria-associated ER membrane (MAM), and the MAM allows 
exchange of Ca2+, ROS, lipids, and nutrients between the ER and the mitochondria, thus 
promoting cellular bioenergetics and metabolism. MAM signaling is important in biological 
processes including lipid biosynthesis, cell death, and macroautophagy 12.  
In eukaryotes, the ER is responsible for secreted and membrane-bound protein folding 
and calcium storage. ROS are generated during oxidative protein folding when molecular 
chaperones, such as protein disulfide isomerases (PDIs), form disulfide bonds in nascent 
polypeptides. Active site cysteine residues in PDIs accept electrons from free thiols in nascent 
polypeptides to generate a disulfide bond. PDIs then transfer the electrons to membrane-bound 
endoplasmic reticulum oxidoreductase 1 (ERO1) to perform another cycle of catalysis 2. ERO1 
further transfers the electrons to O2 and generates H2O2. H2O2 produced by ERO1 in the ER 
lumen is involved in signaling and oxidative protein folding via peroxiredoxin 4 13,14. In 
response to ROS generation, antioxidant enzymes, such as superoxide dismutase, catalase, and 
glutathione peroxidase, maintain redox homeostasis by converting ROS into water and oxygen. 
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Other antioxidant molecules, including reduced glutathione (GSH), vitamin E, and NADH, can 
also inactivate ROS (Figure I-1) 15,16. In the ER, ROS can also be produced by NADPH oxidases 
downstream of PDIA1 activity 17. 
 
Figure I-1. General ROS production in the cell cytoplasm, mitochondria, and ER. The various types of ROS 
interconvert, based on cell requirements and extracellular stimuli. Mitochondria and ER are the two major 
organelles that control ROS signaling. ETC, electron transport chain; ROS, reactive oxygen species; MAM, 
mitochondria-associated ER membrane; ER, endoplasmic reticulum; SOD, superoxide dismutase; NADPH, 
nicotinamide adenine dinucleotide phosphate, reduced. 
 
The MAM was first identified in 1986 as a major site of phospholipid synthesis and 
transportation and is now known to be essential for calcium homeostasis, energy metabolism and 
other signaling pathways 18–20. High concentrations of ER Ca2+ are released at MAM sites and 
taken up into the mitochondria by the Ca2+ uniporter on the inner mitochondrial membrane 21. 
ROS generated by either the ER or mitochondria in H2O2 nanodomains generated by cristae can 
localize at the MAM interface and perturb calcium signaling 22 (Figure I-1). Importantly, ERO1, 
a key regulator of oxidative stress in the ER, is enriched at the MAM interface and regulates 
calcium flux 23,24. ERO1 localization at the MAM interface demonstrates the role of redox 
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signaling on calcium flux through the mitochondria. ERO1 does not cross the MAM but may 
exert its effect via diffusible H2O2. Dysfunction of the ER-mitochondrial crosstalk at the MAM 
has been implicated in neurological diseases such as Alzheimer’s and Parkinson’s, thus ERO1’s 
function at this interface may emerge as a critical driver of MAM dysfunction 25. The oxidizing 
environment of the ER is maintained by the GSH/GSSG ratio to facilitate protein folding (Figure 
I-2) 2,26. Correctly folded and processed proteins are transported out of the ER, while misfolded 
proteins can be either refolded or degraded via the ER-Associated Degradation (ERAD) pathway 
2,27. Therefore, the ER is equipped with a regulatory mechanism to accurately differentiate 
between unfolded/native, misfolded, and correctly folded proteins. The rate of the reaction 
between PDI and GSSG or GSH is rapid, likely contributing to its role as an ER redox sensor 28. 
In a disease state, misfolded and unfolded proteins can accumulate to trigger ER swelling and 
the ER stress response 29. During ER stress, the GSH/GSSG ratio is disturbed, further increasing 
ROS production and distorting the ER redox environment 30. In eukaryotes, the ER is more 
susceptible to oxidative stress due to limited antioxidant enzymes, which indicates its important 
role in the induction of redox imbalance and cellular stress 31. ER stress stimulates the unfolded 
protein response (UPR), which can promote cell survival, or upon prolonged ER stress, 
apoptosis ensues 32. Furthermore, ER stress can induce calcium release from the ER into the 
cytosol. Mitochondria uptake the released Ca2+, causing physical and metabolic changes. For 
example, ROS induces the release of cytochrome c to the cytoplasm, inhibiting complex III 
activity and further inducing ROS in the form of a ubisemiquinone radical intermediate 2. 
Increased Ca2+ ions also stimulate mitochondrial Krebs cycle dehydrogenases and nitric oxide 
synthase, both leading to the elevation of ROS. Most importantly, in a vicious cycle, the ER-
induced mitochondrial ROS may accelerate the release of Ca2+ from the ER to further increase 
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mitochondrial oxidative stress 2. Mitochondrial dysfunction alters ATP generation, which is 
required for protein folding and bond formation in the ER. Thus, mitochondrial dysfunction 
further aggravates ER stress 2. 
A major role of the ER involves calcium storage, and research in recent years furthered 
our understanding of the role in calcium signaling. In addition to being highly oxidizing 
compared to other cellular compartments, the ER differs in that calcium concentrations are 
higher such that free calcium concentration is 100−800 μM 33,34. ROS (O2•−, H2O2, and HO•) also 
communicate bidirectionally with calcium in a complex relationship. Calcium signaling is 
necessary for ROS production, and ROS can regulate calcium signaling 35. In mitochondria, 
calcium promotes metabolism via both the tricarboxylic acid cycle 36 and oxidative 
phosphorylation. In turn, ROS regulates calcium signaling by modulating plasma membrane and 
intracellular calcium channels and Ca2+ ATPases 35. 
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Figure I-2. The ER (pink) is an oxidizing environment, maintained by redox sensor glutathione (GSH/GSSG), with 
a reduction potential much larger than that of the cytoplasm (ER ε: -170 to -185 mV; cytoplasm ε: -280 to -320 mV). 
The oxidizing environment promotes nascent protein folding and disulfide bond formation. ERO1 is a key mediator 
of disulfide bond formation in the ER. Disturbed protein folding may cause ER stress and increased ER ROS 
production, further affecting mitochondrial and cellular metabolism. Reduced polypeptides are oxidized by PDI, 
which transfers its electrons to ERO1. ERO1 is reoxidized by oxygen and produces H2O2. H2O2 is reduced through 
various mechanisms in the ER including catalase, glutathione peroxidases (GPX7 and GPX8), peroxiredoxin 4 
(PRX4), and ascorbate peroxidase (APX). Background image created in Blender 2.79. 
     
ROS-related cancer therapies 
In both tumor and normal cells, low levels of ROS serve as second messengers for 
downstream signaling pathways and promote cell survival and cell proliferation, while increased 
levels of ROS cause oxidative damage to DNA, proteins, and lipids, leading to cellular 
malfunction and cell death 37. Additionally, cancer cells have higher redox requirements than 
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normal cells due to their increased cell metabolism, dysfunctional mitochondria, scarce nutrients, 
and oxygen-poor microenvironment 38. Higher intracellular ROS levels force cancer cells to 
develop robust antioxidant systems to adapt to oxidative stress. Cancer cells are more vulnerable 
to redox modulators than normal cells due to their strong dependence on intrinsically high levels 
of ROS and limited antioxidant threshold. Reprogramming energy metabolism and oxidative 
stress are also two hallmarks of cancer 39–42. Therefore, treating cancer with small molecule 
redox modulators may overwhelm cancer cells selectively. Several redox modulators are under 
review in clinical trials to evaluate efficacy and safety profiles in cancer 10-14. ARQ761, a beta-
lapachone prodrug that reacts with NAD(P)H quinone dehydrogenase 1 (NQO1) to generate 
ROS, showed modest efficacy in an open-label, dose-escalation Phase I study 43. ARQ761 is 
currently in a Phase II clinical trial with gemcitabine/nab-paclitaxel in patients with advanced 
pancreatic cancer who have not been treated with gemcitabine 44. Napabucasin is an orally-
administered cancer stemness inhibitor with a quinone scaffold and has been tested in Phase III 
clinical trials in multiple cancers 45–47. Napabucasin inhibits Signal Transducer and Activator of 
Transcription 3 (STAT3) signaling and increases ROS levels predominately by NQO1 
bioactivation. There are also other ROS-modulating agents under investigation in cancer 
treatment (Figure I-3) 48–51. Therefore, regulating cellular ROS is a promising method to treat 
cancer. In the following chapters, I hypothesize that redox modulators are effective in treating 
pancreatic cancer, and I aim to understand the working mechanisms of the newly discovered 
ROS modulators. 
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Figure I-3. Structures of select redox modulators under investigation in cancer. 
 
Pancreatic cancer is the fourth leading cause of cancer death in the United States, and its 
incidence and mortality rates are continuing to increase worldwide 52,53. It is predicted to be the 
second leading cause of cancer death in the USA by 2030 53,54. Pancreatic cancer is primarily 
diagnosed at a late stage because early-stage symptoms are non-specific. The 5-year survival rate 
at the advanced stage is only around 3% 52. Conventional chemotherapies show only modest 
efficacy in pancreatic cancer because of drug resistance and systemic toxicity, including the 
current standard-of-care, FOLFIRINOX (folinic acid, 5-fluorouracil (5-FU), irinotecan, and 
oxaliplatin), and gemcitabine together with nab-paclitaxel 53,55. Therefore, it is imperative to find 
new improved therapies to treat pancreatic cancer, and I aim to use redox modulators to treat this 
disease. 
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Next-generation sequencing to assist mechanistic studies 
ROS-modulating compounds display cancer-specific cytotoxicity and anti-tumor efficacy; 
however, the involved signaling pathways, working mechanisms, and affected targets of ROS 
are complex. It remains considerably challenging to identify the specific targets and illustrate the 
mechanisms of action (MOAs) of each anti-cancer therapeutic agent, even for the FDA-approved 
drugs. The advancement of next-generation sequencing and bioinformatics techniques opens a 
new avenue for investigating the drug targets and MOAs. These methods provide insights into 
the changes of transcriptomic profiles and downstream signaling, and facilitate studies of cancer 
genomics, diagnosis, and treatment 56,57. In my studies, I used the bromouridine-labeled RNA 
sequencing (Bru-seq) technique to determine the induced and repressed genes in response to our 
redox modulators, and ultimately identify the affected signaling pathways and potential targets. 
Bru-seq was developed by Dr. Mats Ljungman’s lab to assess the newly synthesized RNA in 
cells 58. Bromouridine was added to cells at the last 30 min of drug treatments to label the newly 
synthesized RNAs. The bromouridine-containing RNAs were captured using anti-BrdU 
antibodies conjugated to magnetic beads and converted to cDNA libraries (Illumina TrueSeq) 
that were sent for deep sequencing at the University of Michigan Sequencing Core. This 
technique could provide information on the direct changes of transcriptome caused by the 
compounds instead of the steady states of mature RNAs. 
With the Bru-seq data, I further used bioinformatics tools, such as Gene Set Enrichment 
Analysis (GSEA) and Search Tool for the Retrieval of Interacting Genes/proteins (STRING) to 
determine the enriched gene sets after compound treatments. Publicly available databases, 
including The Cancer Genome Atlas (TCGA), Connectivity Map (CMAP), and Human Protein 
Atlas (HPA) assist the discovery of new genes as potential pharmacodynamics biomarkers 
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involved in the therapeutic pathways. These analyses help generate hypotheses of MOAs or 
targets of redox modulators, which could be further tested using corresponding assays, such as 
immunoblot, siRNA knockdown, and Cellular Thermal Shift Assay (CETSA). 
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CHAPTER II 
ROS-Related Genes in Pancreatic Cancer  
Pancreatic cancer, of which pancreatic ductal adenocarcinoma (PDAC) is the major 
subtype, remains a devastating disease lacking early diagnosis and effective treatment. Therefore, 
it is essential to discover novel biomarkers to facilitate disease-monitoring and new targets for 
drug discovery. A few studies have been conducted to identify and illustrate the complex ROS 
signaling pathways and to discover new biomarkers using various tools, including mass 
spectrometry-based proteomics, transcriptome sequencing, and computational modeling 1–5. A 
survival analysis of 73 known oxidative stress genes in a panel of cancer cells using the TCGA 
data portal revealed that FoxM1, thioredoxin, and superoxide dismutase genes may affect the 
overall survival of cancer patients 1. ROS-modulating compounds have shown potential 
applications in treating pancreatic cancer, and we aim to evaluate how ROS-related genes are 
involved in disease progression and survival 6,7. In this chapter, I used a combination of Bru-seq 
nascent RNA profiling and literature review to identify ROS-related genes and then qualify these 
genes as potential drug targets and biomarkers in pancreatic cancer patients using TCGA RNA-
seq metadata. 
Discovery of novel ROS-related genes in pancreatic cancer cells 
I started with two lists of ROS-related genes.  The first list (referred to as the Bru-seq 
gene list) was experimentally derived by exposing pancreatic cells to H2O2 and measuring the 
transcriptional response. MIA PaCa-2 cells were exposed to H2O2 at three concentrations (50 µM, 
Notes: In preparation to submit to Redox Biology. 
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150 µM, and 300 µM) and then nascent RNA was profiled using Bru-seq. Upregulated (fold 
change > 2) and downregulated (fold change < 0.5) genes were combined to create a collection 
of experimentally derived ROS-related differentially expressed genes.  The second list (referred 
to as the literature gene list) was derived from the reported ROS annotated gene sets. We 
collected 1,250 ROS-related genes by combining Molecular Signatures Database (MSigDB) 
ROS gene sets and references (Figure II-1). 
Both the Bru-seq and literature genes were evaluated for association with patient disease 
progression and survival using the pancreatic adenocarcinoma (PAAD) cohort from TCGA. For 
disease progression, RNA-seq gene expression and patient tumor stage and grade were sourced 
from the GDAC Firehose. Patients were stratified into high and low categories by 
pathologic_stage, pathologic_t, and grade.  Patient stages and grades were classified into high 
and low categories by combining patients with lower stage/grade (e.g. I/G1, G2) into a single 
group and comparing to patients with a higher stage/grade (e.g. II, III and IV/G3) into a single 
group.  A Wilcoxon test was used to identify significant differences in log2 RSEM gene 
expression values between categories and p-values were adjusted for multiple testing per disease. 
From the H2O2 Bru-seq gene list, we identified 189 genes with lower expression and 108 genes 
with higher expression in later stages of PDAC tumors. From the literature gene list, 41 were 
found to have lower expression in later stages of PDAC tumors while 56 had higher expression 
in later stage PDAC tumors (Figure II-1). We use “low genes” and “high genes” to indicate the 
association directionality between gene expression and worse patient progression or survival 
(respectively) in Figure II-1. Notably, there were nine common “low genes” and 12 common 
“high genes” between the two lists and Figure II-1B and 1C show the expression of the top three 
genes (ranked by fold change) in each category as stratified by pathological stage. Among the 
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nine common “low genes”, six of them are involved in response to oxidative stress (XPA, 
ERCC8, FXN, SLC23A2, MAPK9, and PSIP1), three are related to oxidative phosphorylation 
(NDUFA11, ATP6V1H, and COX11), and two regulate nucleotide excision repair (XPA and 
ERCC8), based on STRING analysis 8. For the 12 common “high genes”, six are linked to 
cellular response to oxygen-containing compounds (EIF4EBP1, AGTRAP, ZC3H12A, NQO1, 
PSEN1, and SLC9A1), and eight are involved in the cellular response to chemical stimulus 
(SQSTM1, EIF4EBP1, NQO1, SLC9A1, ZC3H12A, CAT, SDC4, PSEN1, and MYBL2). Below, 
we discuss the roles of these genes in ROS signaling and pancreatic cancer. 
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Figure II-1. Two arms of bioinformatics analysis identified ROS-signaling genes related to the progression and 
survival of pancreatic cancer patients. (A) Bru-seq, the left arm, was performed using 50 μM, 150 μM, and 300 μM 
H2O2-treated MIA PaCa-2 cells for 4 h. Literature, the right arm, includes genes from known ROS gene sets and 
bioinformatics literature. The TCGA dataset was used for the progression and survival analysis. Low, the gene is 
significantly decreased in PDAC patients at later stages or with reduced survival rate. High, the gene is significantly 
overexpressed in PDAC patients at later stages or with reduced survival rate. Wilcoxon two sample test (p-adjusted 
< 0.05) was applied for progression analysis, and multi-threshold log rank test (q value < 0.05) and quartile-
threshold cox proportional hazards test (q value < 0.05) were applied for the survival analysis. (B, C) The 
expression of top three genes in different pathological stages of TCGA_PAAD tumors. Low pathological stage: I; 
high pathological stage: II, III, IV. FC, fold change, calculated as mean log2 RSEM of high stage over mean log2 
RSEM of low stage.  
 
Progression analysis of ROS-related genes identified from two arms 
SLC23A2 (FC = -1.59), PSIP1 (FC = -1.45), and NDUFA11 (FC = -1.3) are the top three 
genes with lowest gene expression in late-stage PDAC patients. SLC23A2 (Solute Carrier Family 
23 Member 2) is a vitamin C transporter regulating vitamin C absorption and uptake that affects 
the antioxidant system in response to ROS. SLC23A2 is an important target for drug delivery 
across epithelial membranes, and its expression modulates drug uptake into the cells and may 
affect cancer treatment 9,10. Therefore, SLC23A2 inhibition could enhance the permeability and 
bioavailability of anti-cancer drugs 10. Moreover, polymorphisms of SLC23A2 SNPs are related 
to chronic lymphocytic leukemia biology, clinical outcomes of chemo-drugs in esophageal 
squamous cell carcinoma patients, and gastric cancer risk 11–13. Our study demonstrates that 
SLC23A2 expression is significantly correlated to pancreatic cancer progression, supporting its 
involvement in pancreatic cancer. 
PSIP1 (PC4 and SFRS1 Interacting Protein 1) is a transcription coactivator that 
facilitates binding between RNA polymerase II and DNA to promote gene transcription. It 
shows elevated levels in metastatic invasive ductal carcinoma and is negatively correlated with 
the survival of triple-negative breast cancer (TNBC) patients 14. Additionally, overexpression of 
PSIP1 in prostate cancer cells reduced their sensitivity to lysosomal membrane permeabilization-
inducing chemotherapies 15. Moreover, it has been studied as a stress oncoprotein to protect 
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cancer cells from different environmental stressors, including oxidative stress 16–18. Our analysis 
reveals that PSIP1 has significantly lower expression in later stage TCGA PDAC tumors and 
H2O2 decreases its nascent transcripts. 
NDUFA11 (NADH: Ubiquinone Oxidoreductase Subunit A11) encodes a subunit of the 
membrane-bound mitochondrial complex I, working as an NADH-ubiquinone reductase on the 
mitochondrial ETC 19,20. Mutation of NDUFA11 may cause multiple diseases, such as neonatal 
lactic acidosis and cardiac disorders, due to defects in the respiratory chain 21. Furthermore, 
NDUFA11 SNPs are associated with heart rate variability that is related to cardiac morbidity and 
mortality 22. NDUFA11 expression was increased by long non-coding RNA TERC in lung 
squamous cell carcinoma 22,23. Our analysis shows that it is also related to pancreatic cancer 
progression and may represent a promising therapeutic target. 
MYBL2 (FC = 2.87), EFNA4 (FC = 2.69), and NQO1 (FC = 2.66) are the top three genes 
with the highest fold change when comparing late stage to early stage PDAC tumors. MYBL2 
(MYB Proto-Oncogene Like 2) encodes a nuclear protein in the MYB family of transcription 
factors linked to cell cycle regulation. MYBL2 is an essential upstream transcription factor of 
several genes related to cell proliferation in NSCLC, and its overexpression is associated with 
poor patient survival 24–26. Its potential role as a drug target or biomarker has also been 
demonstrated in breast cancer 27, esophageal squamous cell carcinoma 28, and hepatocellular 
cancer 28,29. In pancreatic cancer patients, microRNA-29a (miR-29a) can downregulate MYBL2 
gene expression to regulate tumorigenesis 30. MYBL2 is also a key downstream gene of 
Akt/FOXM1 signaling, and its overexpression promotes tumor progression in glioma 31. Besides 
cancer, overexpression of MYBL2 protein improves cell viability and inhibits apoptosis in H9c2 
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cardiomyocytes 32. In our analysis, we found higher MYBL2 expression in later stage PDAC 
patients. 
EFNA4 (Ephrin A4) is involved in the cell fate decisions of mammary epithelial cells 33. 
It also regulates the adhesion and cell death of the chronic lymphocytic leukemia cells 34. 
Overexpression of EFNA4 in triple-negative breast cancer (TNBC), ovarian cancer, and 
pancreatic cancer is significantly associated with poor patient outcome 35,36. The knockdown of 
EFNA4 inhibits the motility and invasion of pancreatic cancer cells by affecting the expression 
of epithelial (E)-cadherin and Snail proteins 37. Based on these findings, inhibitors of EFNA4 
have been developed to treat cancers. 2,5-dimethylpyrrolyl benzoic acid suppressed the EFNA4-
Akt pathway and induced apoptosis in PDAC cells, demonstrating anti-tumor efficacy in an 
orthotopic PDAC mouse model 36. PF-06647263, a novel anti-EFNA4 antibody linked to a 
calicheamicin payload, showed limited anti-tumor activity in TNBC and ovarian cancer patients 
in a first-in-human, Phase I study 38. In our study, we show that EFNA4 has increased expression 
in later stage PDAC. This finding suggests value in identifying more effective EFNA4 inhibitors 
for clinical trials in pancreatic cancer. 
NQO1 (NAD(P)H Quinone Dehydrogenase 1) is the most-well studied gene among all 
three genes associated with PDAC disease progression. It encodes a cytoplasmic two-electron 
reductase to detoxify and bioactivate quinone compounds 39. Elevated expression of NQO1 in 
tumor tissues is closely related to tumor progression, aggressiveness, and poor patient prognosis 
in breast, lung, prostate and pancreatic cancer 40–43. Agents inhibiting NQO1 activity have been 
developed and show anti-tumor effects in vitro and in vivo 39. One NQO1 inhibitor, β-lapachone 
(ARQ 501) and its analog are in Phase I and II clinical trials for cancer therapy, highlighting the 
potential role of NQO1 as a therapeutic target. Moreover, the combination of an NQO1 inhibitor 
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and anticancer drugs resulted in improved antitumor activity in multiple cancers 44–46. In our 
analysis, NQO1 expression was significantly associated with stage progression in pancreatic 
cancer patients that is consistent with the literature. In Chapter III, we characterized a redox 
modulator similar to napabucasin in the transcriptomic profile and it may regulate mitochondrial 
proteins via NQO1. 
PDAC disease progression analysis of ROS-signaling genes unique to the Bru-seq arm 
Apart from understanding the roles of common genes between the Bru-seq arm and the 
literature arm, we also investigated differentially expressed genes that were unique to the Bru-
seq arm, which may provide new information about ROS signaling essential for pancreatic 
cancer. Out of the 297 genes related to PDAC tumor progression, we focused on genes with 
clear Bru-seq trace diagrams and dose-dependent changes in response to H2O2. A total of 35 
differentially expressed genes were selected based on manual inspection of Bru-seq trace 
diagrams for further analysis. In order to validate our discoveries from this sequencing arm, we 
also evaluated these genes on their association with disease progression in a separate pancreatic 
cancer study by Bailey et al. 47. Nine out of 24 “high genes” and two out of 11 “low genes” 
displayed significant differential expression in later stage PDAC tumors in both datasets (Table 
II-1, Figure II-2). 
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Figure II-2. Select genes are significantly associated with tumor progression in both TCGA and Bailey datasets and 
were regulated by H2O2. (A) Nine genes overexpressed in later stages of PDAC tumors were downregulated by 
H2O2. (B) Two genes downregulated in later stages of PDAC tumors were upregulated by H2O2. (C) Expression of 
select genes in different pathologic stages of TCGA_PAAD tumors.  
 
 
Table II-1. Summary of genes significantly associated with PDAC tumor progression in each category. Datasets 
contain the TCGA and Bailey datasets. Low, lower expression in later stage tumors. High, higher expression in later 
stage tumors. 
 
 
Category Genes 
Common between 
two arms 
Low (9) SLC23A2, PSIP1, NDUFA11, COX11, FXN, ATP6V1H, XPA, ERCC8, MAPK9 
High (12) MYBL2, EFNA4, NQO1, ZC3H12A, SDC4, SLC9A1, AGTRAP, EIF4EBP1, PSEN1, CAT, OXSR1, SQSTM1 
Unique in Bru-seq 
arm and validated in 
both datasets 
Low (2) FAM222A, ERO1B 
High (9) AGPS, AGTRAP, CDCA2, DOCK5, NFE2L3, PLBD1, PTPN12, PTPN14, ZBTB7B 
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Among the nine overexpressed genes downregulated by H2O2 treatment, AGPS 
(Alkylglycerone Phosphate Synthase) encodes a FAD-binding protein from the 
oxidoreductase/transferase type 4 family. AGPS is a rate-limiting enzyme in plasmalogen 
synthesis, and its expression is affected by amyloid precursor protein levels and ROS production 
in Alzheimer’s disease 48. AGPS protein is critical for ether lipid synthesis and is upregulated in 
multiple cancers, such as glioma and hepatic carcinoma 49,50. Knockdown of AGPS reduced 
expression of multi-drug resistance and anti-apoptosis proteins, leading to drug uptake and 
cancer cell death 49. Inhibition of AGPS also suppressed the migration of glioma U-87 MG cells 
51. Several inhibitors of AGPS have impaired cell proliferation, epithelial to mesenchymal 
transition (EMT), and migration, especially in cancers overexpressing AGPS protein 52,53. Our 
study is the first to show the upregulation of AGPS in later stage PDAC tumors and we suggest 
AGPS inhibitors may also be repurposed for pancreatic cancer treatment. 
AGTRAP (Angiotensin II Receptor Associated Protein) is involved in the negative 
regulation of angiotensin II signaling via interaction with the angiotensin II type I receptor. 
Activation of aortic vascular AGTRAP can inhibit the ROS-p38 MAPK/JNK pathway and 
suppress pathological aortic hypertrophy 54. Additionally, knockout mice displayed age-related 
pathological changes in the kidney 55. AGTRAP is overexpressed in squamous cell carcinomas 
and melanoma tumors, but it has conflicting associations with disease prognosis 56,57. We 
observed upregulation of AGTRAP in later stage pancreatic cancer patients, suggesting its 
potential as a prognostic biomarker in pancreatic cancer. 
CDCA2 (Cell Division Cycle Associated 2) is a cell cycle regulator related to cell 
proliferation and tumor progression. The relationship between CDCA proteins and ROS is not 
clear. CDCA2 can promote cancer cell growth, and is upregulated in multiple cancers (colorectal 
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carcinoma, lung adenocarcinoma, and PDAC) and associated with tumor progression and 
prognosis 58–60. More studies are needed to understand its cellular involvement in the ROS 
signaling pathways. 
DOCK5 (Dedicator of Cytokinesis 5) is a guanine nucleotide exchange factor for small 
Rho family G proteins. Its spliced variant promoted proliferation, migration, and invasion of 
HPV-negative head and neck squamous cell carcinoma (HNSCC) 63. It works together with 
DOCK2 to regulate chemotaxis, ROS production, and formation of extracellular traps in 
neutrophils 64. We observed a positive association of DOCK2 expression with later stage tumors, 
implying possible biomarker relevance or therapeutic target potential. 
The relationships between PLBD1 (Phospholipase B Domain Containing 1), ZBTB7B 
(Zinc Finger and BTB Domain Containing 7B), and ROS are not clear. PLBD1 was associated 
with the initiation and progression of carotid paragangliomas with a high mutation rate 65. 
ZBTB7B is a critical protein in mature CD4+ T cells that suppresses CD8-lineage gene 
expression, and it modulates thymic development and lymphomagenesis 66–68. We identified a 
novel association of the expression of these genes and disease progression in two pancreatic 
cancer datasets to robustly support their relevance to pancreatic cancer disease. 
PTPN12 (Protein Tyrosine Phosphatase Non-Receptor Type 12) and PTPN14 (Protein 
Tyrosine Phosphatase Non-Receptor Type 14) encode protein tyrosine phosphatases that are 
drug targets for multiple cancers 69–71. The link between PTPN14 and ROS signaling is not well 
understood, but some studies on its functions in cancers have been performed. Knockdown of 
PNPT14 led to an increase in neuroblastoma cell migration and invasion; however, the opposite 
effect was observed in gastric cancer cells where the suppression of PTPN14 inhibited EMT 69,72. 
In gastric cancer cells, PTPN1 accelerated proliferation and migration by increasing the 
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phosphorylation of the oncoprotein Yes-associated protein (YAP) in the Hippo signaling 
pathway 72. Furthermore, PTPN14 overexpression correlated with low survival in colorectal 
cancer patients 70. Conversely, a separate study determined that PNPT14 was a tumor suppressor 
in the p53-PTPN14-YAP axis in pancreatic cancer 71. We believe further studies are needed to 
elucidate the connection between PTPN14 and ROS signaling in pancreatic cancer. 
FAM222A and ERO1B were validated in both TCGA and Bailey datasets, and their lower 
expression correlated with later stages of pancreatic cancer (Figure II-2). H2O2 was found to 
increase the transcription of these genes in MIA PaCa-2 cells, indicating a connection with ROS 
signaling. The function of FAM222A (Family with Sequence Similarity 222 Member A) is not 
fully understood in cancer and ROS signaling. ERO1B (Endoplasmic Reticulum Oxidoreductase 
1 Beta) encodes an oxidoreductase involved in disulfide bond formation in the endoplasmic 
reticulum. ERO1A and ERO1B are two paralogs from the ERO1 family in higher eukaryotes 80. 
ERO1A is ubiquitously expressed in multiple human tissues, while ERO1B is more exclusively 
in secretory tissues, such as the pancreas 81. ERO1β is induced by unfolded protein stress and is 
approximately twice as active as ERO1ɑ as an oxidase 82. Knockdown of ERO1B, a downstream 
target of ATF6a, significantly increased the sensitivity of U2OS osteosarcoma cells to cisplatin 
treatment 83. Low expression of ERO1B is associated with poor patient overall survival in 
pancreatic cancer, and it is increased in pancreatic neuroendocrine tumors 84,85. In our study, we 
showed that ERO1B expression was upregulated in earlier stages/grades of PDAC tumors in the 
both datasets. 
Survival analysis of ROS signaling genes in both arms 
We identified that 16 genes were significantly associated with pancreatic cancer 
progression and patient survival. In the Bru-seq arm, the overexpression of PTPN14 and 
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NFE2L3 (Nuclear Factor, Erythroid 2 Like 3) genes and lower expression of ZNF547 and 
KIAA1683 genes are significantly associated with a reduced survival rate in PDAC patients in 
the TCGA dataset (Figure II-3). NFE2L3 (Nrf3) is in the same nuclear transcription factor 
family as Nrf2, which has been extensively investigated for its known roles in oxidative stress 
and cancer [88,89]. Nrf2 expression has been shown to increase promoter activity of 
peroxiredoxin 6, an antioxidant enzyme, while Nrf3 displayed opposite effects 72. Nrf3 is 
upregulated in multiple tumor samples compared to normal tissues, and promotes 20S 
proteasome assembly via increasing POMP expression, thus degrading the tumor suppressors 
p53 and Rb 73, 74. Silencing of Nrf3 decreased cell proliferation and tumor growth in colorectal 
cancer by increasing DUK expression and inhibiting CDK1 activity 75. Its downregulation also 
induced cell cycle arrest at the G0/G1 Phase in colorectal cancer 76. In pancreatic cancer, we 
found increased expression of Nrf3 was associated with reduced overall survival. Meanwhile, 
other studies have shown that NFE2L3 was relevant to poor prognosis of pancreatic cancer 
patients when considering cumulative survival rate and disease-free survival 73, 74. Therefore, our 
analysis is consistent with current studies, supporting the potential role of NFE2L3 as a 
therapeutic target or prognostic biomarker in PDAC. The biological functions of ZNF547 (Zinc 
Finger Protein 547) and KIAA1683 (IQCN, IQ Motif Containing N) are relatively unknown in 
cancer and ROS signaling.  We believe these novel findings represent opportunities to further 
understand the connection between ROS signaling and poor pancreatic patient outcome.  
KPNA4 (Karyopherin Subunit Alpha 4) is the only gene showing association with 
reduced patient survival and tumor progression from the literature arm. KPNA4 is a downstream 
target of several microRNAs that are tumor suppressors and associated with poor prognosis and 
reduced survival of glioblastoma and hepatocellular carcinoma 86,87. KPNA4 protein is 
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overexpressed in cutaneous squamous cell carcinoma, and it increases cell proliferation and 
resistance to cisplatin 88. Additionally, inhibition of KPNA4 slowed the metastasis of prostate 
cancer 89. Therefore, KPNA4 may be a worthy therapeutic target in cancers, including PDAC. 
 
Figure II-3. Four genes are significantly related to the overall survival and progression of pancreatic cancer patients 
in the TCGA dataset from the Bru-seq gene list. (A) Higher expression of NFE2L3 and PTPN14 significantly 
correlates with reduced overall survival. (B) Lower expression of ZNF547 and KIAA1683 significantly correlates 
with decreased overall survival. 
 
Correlation analysis of genes associated with PDAC progression and survival 
In an effort to identify genes that are correlated with the four survival genes (NFE2L3, 
PTPN14, ZNF547, and KIAA1683) from the Bru-seq arm in the TCGA dataset, a correlation 
analysis was performed to further understand their roles in pancreatic cancer. Gene co-
expression analysis can provide insight to transcriptional programs for which these genes 
participate and generate hypotheses for future experimental validation to reveal pathway 
interactions. Using log2 RSEM values from the TCGA PAAD cohort (N = 178), we calculated 
Spearman correlation to quantify the co-expression between these four genes and all other genes 
measured.  Three genes (CBX3, MET, and ECT2) were positively correlated with NFE2L3 with a 
rho value over 0.6 (Figure II-4A, 4F). Few studies delve into the biological relationship between 
these three genes and NFE2L3. MET is a candidate upstream oncogene of ECT2, and 
overexpression of ECT2 in lung adenocarcinoma and glioblastoma is associated with poor 
patient survival 5,90. In the TCGA PAAD dataset, 128 genes were positively, and 22 genes were 
 
 
 
 
 
 
 28 
negatively co-expressed with PTPN14 (Figure II-4B, 4E, 4F). Protein-protein interaction 
analysis was conducted using STRING. The 128 genes positively correlated with PTPN14 were 
enriched for KEGG pathways related to the regulation of actin cytoskeleton, focal adhesion, 
PI3K-Akt signaling, and RAS signaling, suggesting PTPN14 may be involved in these pathways 
(Figure II-4G). This suggests that PTPN14 may be involved in these pathways. Connections 
between PTPN14 and focal adhesion, modulation of cell proliferation, migration, and invasion in 
cancers have been studied 69,72,91. YAP1 is the sixth most positively correlated gene, and its 
relationship with PTPN14 has been described previously 72. The biological relationships between 
the top five positively co-expressed genes (FER, KLF7, AHNAK, RSF1, and MINDY2) and 
PTPN14 remain unclear, and these relationships are worthy of future investigation. No KEGG 
pathways were significantly enriched for the negatively correlated genes. 
ZNF547 and KIAA1683/IQCN are two genes associated with reduced survival and later 
stage of disease progression. We also determined that two genes (ZNF814 and ZNF419) 
positively correlated with ZNF547, and 33 with KIAA1683/IQCN (Figure II-4C, 4D, 4F). The 
biological functions of ZNF814 and ZNF419 are poorly understood. One study identified 
ZNF814 had significant mutations (c.1010C>T and a synonymous mutation) in familial 
hemangioblastomas 92. In HeLa cells, alternative splicing of ZNF419 may remove a DNA-
binding domain from the protein, thus affecting downstream cellular targets and functions 93. 
Moreover, a polymorphism in the splice donor site of ZNF419 resulted in the minor 
histocompatibility antigen ZAPHIR, which is involved in the specific CD8+ T cell responses in 
selective graft-versus-tumor immunity, thus ZNF419 could be important in immunotherapy 94. 
These findings provide candidate biological functions and cellular pathways that ZNF547 may 
be involved in. 
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Of the 33 genes positively co-expressed with KIAA1683/IQCN, four contain an RNA-
binding domain (CELF6, CIRBP, RBM5, and SAFB2). There are no significant KEGG pathways 
enriched from this gene list. The top two genes are CELF6 and ZMAT1. CELF6 is an RNA-
binding protein that regulates cell proliferation and cell cycle in a p53- and/or p21-dependent 
manner, and it modulates p21 stability by binding to the 3’-UTR of p21 transcripts 95. In another 
study of the Xinjiang Uygur population, the minor allele “C” of rs4777498 in CELF6 correlated 
with the increased risk of cervical cancer 96. ZMAT1 has six transcripts, and three of them are 
protein-coding. ZMAT1 transcript variant 2, a long non-coding RNA, is downregulated in gastric 
cancer tissue compared with adjacent normal tissue, and its expression is lower in advanced-
stage disease and patients with shorter disease-free intervals 97. KIAA1683/IQCN may be related 
to these functional relationships and transcriptional regulation, but its detailed association with 
pancreatic cancer pathways remains to be determined. 
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Gene  Entrez ID # of Positive 
Correlations 
# of Negative 
Correlations 
NFE2L3 9603 3 0 
PTPN14 5784 128 22 
ZNF547 284306 2 0 
KIAA1683/IQCN 80726 33 0 
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     G 
 
KEGG pathway 
(FDR < 0.01) 
Genes 
actin cytoskeleton EGFR, ENAH, IQGAP1, ITGA2, ITGAV, ITGB1, KRAS, NCKAP1, 
PAK2, PDGFC, PIK3CA, VCL 
focal adhesion EGFR, ITGA2, ITGAV, ITGB1, PAK2, PDGFC, PIK3CA, VCL 
PI3K-Akt signaling ATF2, EGFR, ITGA2, ITGAV, ITGB1, KRAS, OSMR, PDGFC, 
PIK3CA, PPP2R5E 
RAS signaling EGFR, KRAS, PAK2, PDGFC, PIK3CA, RASA2, RASAL2, REL 
 
Figure II-4. Correlation analysis of NFE2L3, PTPN14, ZNF547 and KIAA1683/IQCN in PDAC patients from 
TCGA database. (A-D) Top two genes with positive correlations with NFE2L3, PTPN14, ZNF547 or 
KIAA1683/IQCN. (A) NFE2L3: CBX3 and MET. (B) PTPN14: FER and KLF7. (C) ZNF547: ZNF814 and ZNF419. 
(D) KIAA1683/IQCN: CELF6 and ZMAT1. (E) Top two genes with negative correlations with PTPN14: ZNF688 
and TRMU. (F) Summary of all co-expressed genes. Genes with abstract correlation score (|rho|) over 0.6 were 
counted as significant. Correlations were calculated using Spearman statistics on TCGA dataset, and the log2 UQ 
normalized RSEM data were downloaded from GDAC Firehose. Gene expression is required in at least 50% of 
patients. (G) STRING analysis of 128 positively co-expressed genes with PTPN14. Red circle highlights the major 
enriched KEGG pathways as listed in the table. 
 
Conclusions 
Reactive oxygen species are essential signaling messengers in cancer cells and redox 
modulators continue to be investigated as promising anticancer agents. It is critical to understand 
the genes, pathways, and mechanisms involved in ROS signaling to effectively target and 
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harness the therapeutic potential of this important process. In this study, we used Bru-seq to 
profile the nascent RNA of H2O2-treated pancreatic cancer cells to discover novel ROS-related 
genes. We confirmed the clinical significance of genes involved in ROS signaling using several 
previously published pancreatic patient cohorts by quantifying association with pancreatic 
cancer disease progression and survival. Collectively, we identified nine genes with lower 
expression and 12 genes with higher expression in more advanced PDAC tumors from both arms, 
confirming their association with pancreatic cancer progression. More importantly, for the first 
time, we identified nine ROS-related genes with positive and two with negative associations 
with disease progression in both TCGA and Bailey pancreatic cancer datasets. In addition, three 
genes (NFE2L3, PTPN14, and KPNA4) had higher expression and two genes (ZNF547and 
KIAA1683/IQCN) had lower expression in TCGA patients with a reduced survival time. 
However, the survival analysis results were not supported by the Bailey dataset. These 
discrepancies may be due to different cohorts of pancreatic cancer patients, different subtypes of 
pancreatic cancer patients, and different measurement methods 47,98. Overall, our findings 
combined with previous studies in various cancers suggest these genes represent prognostic 
biomarkers or therapeutic targets in pancreatic cancer, and further investigation into their 
biological function and signaling pathways is warranted. 
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CHAPTER III 
A Novel Redox Modulator Induces a GPX4-mediated Cell Death Dependent on Iron and 
Reactive Oxygen Species 
 Previously, we developed a series of quinazolinedione-based ROS inducers that were 
tested for utility in pre-clinical models of pancreatic cancer (Chart 1). In this study, we show for 
the first time that QD394 displayed highly similar transcriptomic profiles with napabucasin, 
suggesting similar downstream signaling effects. Combinations with cell death signaling 
inhibitors revealed that QD394 induced ferroptosis but not caspase-dependent apoptosis, 
necroptosis, or autophagy. We further demonstrate that QD394 induces lipid peroxidation, iron-, 
ROS-, and glutathione peroxidase 4 (GPX4)-mediated cell death, all of which are closely related 
to ferroptosis. Ferroptosis was first identified in 2012 to represent an iron-dependent regulated 
cell death with increased lipid peroxidation 1. Intrinsic mechanisms of ferroptosis depend on the 
activity of phospholipid peroxidase GPX4 and lipid peroxidation 2,3. At least four classes of 
ferroptosis inducers have been developed, including (1) SLC7A11 inhibitor (erastin), (2) GPX4 
inhibitor (RSL3), (3) FIN56 (depleting GPX4 protein), and (4) FINO2 (indirectly inhibiting 
GPX4) 2. Ferroptosis inducers show synergistic anti-tumor effects with select chemotherapies 4 
and sensitize cancer cells to radiation 5. We also observed synergy between QD394 and select 
FDA-approved drugs, suggesting that combination studies with redox modulators as ferroptosis 
inducers could be a viable approach to treat pancreatic cancer.  
Notes: In preparation to submit to Journal of Medicinal Chemistry. 
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Additionally, we performed proteomics analysis and observed a significant decrease in 
LRPPRC and PNPT1 expression, two proteins involved in mitochondrial RNA catabolic 
processes. The expression of these two genes is negatively correlated with the survival of 
pancreatic cancer patients. Furthermore, a pharmacokinetics (PK)-guided lead optimization 
campaign was conducted to develop a QD394 analog, QD394-Me, with improved PK properties. 
  
Results 
QD394 shows remarkable similarity to napabucasin and H2O2 in transcriptomic profiles 
Among 11 originally synthesized analogs, QD394 had the highest cytotoxicity in MIA 
PaCa-2 cells and similar cytotoxicity in PANC-1 and BxPC-3 cells (Table III-1). I have also 
tested QD394 in HPNE and HFF-1 cell lines, and its IC50 values are 2-fold higher than that in 
MiaPaca-2. QD394 induced the highest level of intracellular ROS after 1 h compound treatment 
(Figure III-S1). To better elucidate its mechanism of action, we performed Bru-seq, which is a 
nascent RNA-seq technique that uses bromouridine to label newly synthesized RNAs 6. This 
method detects immediate changes in the transcriptome caused by drugs to aid in the 
understanding of the potential mechanisms of action. We discovered that the transcriptomic 
profile of QD394 was highly similar to that of napabucasin and H2O2. The shrunkenLFC 
(shrunken log2FoldChange) of genes in QD394 Bru-seq samples significantly correlated with 
that of the napabucasin (r = 0.92) and H2O2 (r = 0.88) samples, indicating similar transcription 
regulation (Figure III-1A). ShrunkenLFC reduces the effect of low-expressing genes resulting in 
over-inflated Log2FoldChange values. Gene Set Enrichment Analysis (GSEA) revealed 82 
upregulated and 51 downregulated enriched gene sets in common between QD394 and 
napabucasin Bru-seq samples using the C2 curated gene sets from Molecular Signatures 
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(MSigDB) Database v7.0 with FDR below 0.001 (Figure III-1B, C). For the Hallmark and 
KEGG pathway gene sets shared between QD394 and napabucasin, TNFA signaling, UV 
response, and hypoxia hallmark gene sets were upregulated, and RNA degradation KEGG gene 
set was downregulated (Figure III-1D, E). TNF signaling and ROS are interconnected in the 
regulation of cell homeostasis, survival, and death in inflammatory diseases and cancers. ROS is 
closely related to TNF-related downstream signaling, such as NF-κB and JNK activation, and 
TNF can induce antioxidant NRF2 pathway to protect cells from elevated ROS 7. UV radiation 
can cause DNA damage and corresponding cell death via oxidative stress 8,9. Moreover, cellular 
and mitochondrial ROS activate a series of transcription factors (TFs), which trigger the 
expression of a number of genes involved in the hypoxic response 10,11. It is interesting to note 
that QD394 affects RNA degradation in the KEGG pathway gene set, and this is consistent with 
our proteomics study (see below). 
    Since napabucasin is a STAT3 signaling inhibitor and exhibited a similar transcriptomic 
profile as QD394, we sought to determine whether QD394 affected STAT3 signaling. Indeed, 
QD394 inhibited the phosphorylation of STAT3 in MIA PaCa-2 and PANC-1 cells, and it 
increased the phosphorylation of H2AX, a DNA damage biomarker (Figure III-1F). 
                                        
Chart 1. Design of novel quinazolinedione-based ROS modulators. 
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Figure III-1. Transcriptomic profile of QD394 is similar to that of napabucasin (napa) and H2O2. (A) Pearson 
correlation between QD394, napabucasin, and H2O2 samples calculated in R. ShrunkenLFC was used to build 
heatmaps. (B, C) Upregulated and downregulated gene sets in GSEA from QD394 and napabucasin Bru-seq 
samples. GSEA plots of upregulated (D) and downregulated (E) enriched gene sets from the QD394 samples that 
are shared with napabucasin are depicted. FDR < 0.001. NES, normalized enrichment score. (F) Cells were treated 
with QD394 for 4 h at indicated concentrations and analyzed by immunoblot with STAT3, pSTAT3, GAPDH, and 
pH2AX antibodies.  
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Table III-1. Cytotoxicity of QD compounds in MIA PaCa-2, PANC-1, and BxPC-3 cancer cell lines. The IC50 (μM) 
is shown as mean ± sd. Mean and standard deviation were calculated from three independent experiments. 
 
ID 
IC50 (μM) 
MIA PaCa-2 PANC-1 BxPC-3 
QD385   2.4 ± 0.1   2.3 ± 0.3   5.1 ± 1.4 
QD386   9.7 ± 4.0   4.4 ± 1.9   10.1 ± 2.8 
QD387   3.1 ± 0.2   1.9 ± 0.2   3.3 ± 1.4 
QD388   2.4 ± 0.6   1.4 ± 0.5   2.5 ± 0.9 
QD389   1.5 ± 0.3   0.8 ± 0.3   2.3 ± 0.4 
QD390   3.1 ± 1.5   4.7 ± 1.5   4.5 ± 0.6 
QD391   2.2 ± 0.7   1.6 ± 0.8   2.6 ± 0.3 
QD392   1.5 ± 0.7   2.3 ± 0.3   1.6 ± 0.6 
QD393   1.2 ± 0.2   0.9 ± 0.4   0.5 ± 0.1 
QD394   0.64 ± 0. 04   0.34 ± 0.03   0.9 ± 0.2 
QD395   2.0 ± 0.7   0.8 ± 0.2   2.7 ± 0.4 
QD394-Me   3.63 ± 0.37   0.38 ± 0.01   0.87 ± 0.15 
 
 
 
Figure III-S1. Characterization of originally synthesized QD394 analogs. (A) ROS-inducing capability of 11 QD394 
analogs measured by CM-H2DCFDA dye in MIA PaCa-2 and PANC-1 cells. RFU, relative fluorescence unit. All 
analogs were tested at 10 μM, and tert-butyl hydroperoxide  (TBHP) was tested at 200 μM. (B) QD394 is one of the 
most potent compounds in the colony formation assay in MIA PaCa-2 cells. 
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QD394 induces ROS-mediated cell death and decreases the GSH/GSSG ratio 
As a redox modulator, QD394 caused time-dependent cellular ROS accumulation within 
the first 4-hour treatment in MIA PaCa-2 cells (Figure III-2A). The significant increase of ROS 
level could be reduced in 30 minutes by the antioxidant N-acetylcysteine (NAC) (Figure III-2B). 
Additionally, NAC significantly increased the IC50 of QD394 from 0.53 μM to 1.11 μM (Figure 
III-2C) and rescued colony formation inhibition by QD394 (Figure III-2D). Thus, the 
cytotoxicity of QD394 is partially dependent on ROS induction.  
    Glutathione is a well-known cellular ROS scavenger. In the GSH/GSSG-Glo assay, 
QD394 significantly decreased the GSH/GSSG ratio at both 2 h and 4 h treatment, similar to 
napabucasin (Figure III-2E). The decrease of ratio is due to reduced GSH level or increased 
GSSG level or both. The reduction from QD394 treatment was caused by oxidation of GSH to 
GSSG, rather than the direct decrease of GSH level (Figure III-S2). BSO is an inhibitor of GSH 
synthesis, and both napabucasin and buthionine sulfoximine (BSO) significantly lowered GSH 
level (Figure III-2E, S2). 
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Figure III-2. QD394 increases cellular ROS level and reduces GSH/GSSG ratio in MIA PaCa-2 cells. (A) QD394 
increased fluorescence (RFU) indicating cellular ROS generation across treatment time (0 - 4 h). TBHP was used as 
a positive control. (B) At 30 min, significant increase of ROS was determined in QD394- and TBHP-treated cells, 
and NAC (3 mM) reduced the elevated ROS levels. ** denotes p < 0.005, *** denotes p < 0.0005. (C) NAC 
significantly decreased the cytotoxicity of QD394 in the MTT assay. (D) NAC protected the inhibition of colony 
formation caused by QD394. (E) QD394 reduced cellular GSH/GSSG ratio mainly resulting from GSSG formation. 
RLU, relative luminescence unit. * denotes p < 0.05, ** denotes p < 0.005, *** denotes p < 0.0005. 
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Figure III-S2. QD394 did not change GSH level significantly, but napabucasin and BSO did. RLU, relative 
luminescence unit. * denotes p < 0.05, ** denotes p < 0.005, *** denotes p < 0.0005.  
 
QD394 causes iron-dependent and GPX4-mediated cell death 
Since we observed that QD394 modulated the GSH/GSSG ratio and its cytotoxicity was 
dependent on ROS, we hypothesized that QD394 could induce ferroptosis. To determine the cell 
death mechanism, we combined QD394 with a panel of signaling inhibitors (Table III-2). We 
identified that deferoxamine (DFO) and deferasirox, two iron chelators, prevented cell death 
caused by QD394, indicating iron is a contributing factor for its cytotoxicity (Figure III-3A, S3). 
Two known ferroptosis inhibitors had different effects on cell death rescue. Liproxstatin-1 
modestly rescued cell death caused by QD394, while ferrostatin-1 did not. Z-VAD (a caspase-
dependent apoptosis inhibitor) and necrostatin-1 (a necroptosis inhibitor) did not rescue cell 
death, and chloroquine (an autophagy inhibitor) slightly rescued cell death in the colony 
formation assay (Figure III-S3). Interestingly, necrostatin-1 blocked the inhibition of colony 
formation caused by napabucasin, indicating that cell death by napabucasin may proceed via 
necroptosis. The link between napabucasin and necroptosis has not been reported previously. 
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Moreover, these results demonstrate that QD394 and napabucasin have different cell death 
mechanisms. 
    The final step in ferroptosis is an increase in lipid peroxidation 1–5. We measured the lipid 
ROS level in QD394-treated cells using the BODIPY C11 dye to validate QD394-induced 
ferroptosis cell death. QD394 significantly increased lipid ROS in a dose-dependent manner 
(Figure III-3B). TBHP (an ROS inducer), RSL3 (a GPX4 inhibitor), and erastin (an SLC7A11 
inhibitor) all increased lipid ROS. Besides iron and lipid peroxidation, GPX4 is another central 
mediator of ferroptosis. GPX4 catalyzes the reduction of hydrogen peroxide, organic 
hydroperoxides, and lipid hydroperoxides, and thereby protects cells against oxidative damage 12. 
Therefore, we investigated whether there is a connection between QD394 and GPX4. In the 
cellular thermal shift assay (CETSA), QD394 destabilized GPX4 protein, indicated by the 
reduction in its melting temperature (from 60.34 °C to 57.62 °C) in MIA PaCa-2 cells (Figure 
III-3C). The destabilization of GPX4 by QD394 was also observed in PANC-1 cells (Figure III-
S4). Binding to a protein generally stabilizes it, however, QD394 destabilizes GPX4 and it may 
be caused by an alternative binding mode or indirect interaction between them. Furthermore, the 
cytotoxicity of QD394 was significantly decreased in MIA PaCa-2 cells with GPX4 knocked 
down using siRNA, further suggesting that QD394 regulates GPX4-mediated cell death (Figure 
III-3D). Additionally, QD394 rescued the cytotoxicity of RSL3 in pancreatic cancer cells, 
suggesting that QD394 targets GPX4 (Figure III-3E). In summary, QD394 induces an iron-
dependent and GPX4-mediated cell death, which is closely related to ROS induction. 
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Table III-2. Select cell death inhibitors that were combined with QD394 in pancreatic cancer cells. 
 
Cell death Target Inhibitor 
Apoptosis All caspases  Z-VAD-FMK  
Necroptosis RIP1 kinase  Necrostatin-1  
Selective inhibitor of RIP1  Necrostatin-1s 
Ferroptosis Iron; iron-dependent prolyl hydroxylases; lysosomal 
ROS inhibitor by chelating lysosomal redox-active iron  
Deferoxamine (DFO), 
deferasirox 
Inhibit autooxidation of lipids by trapping peroxyl 
radicals; not rescue H2O2-induced cell death 
Ferrostatin-1  
Inhibit ferroptosis induced by L-buthionine 
sulphoximine (BSO), erastin and (1S,3R)-RSL3; inhibit 
autooxidation of lipids by trapping peroxyl radicals  
Liproxstatin-1  
Autophagy  Impair autophagosome fusion with lysosomes  Chloroquine  
Inhibit PI3K activity and the initial phase of the 
autophagic process 
3-Methyladenine 
Parthanatos PARP inhibitors  Olaparib  
AIF release inhibitors  N-phenylmaleimide  
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Figure III-3. QD394 induces iron-dependent and GPX4-mediated ferroptosis in MIA PaCa-2 cells. (A) DFO 
decreased the inhibition of colony formation caused by QD394. (B) QD394 significantly induced lipid peroxidation 
after 24 h treatment, similar to TBHP, RSL3, and erastin. * denotes p < 0.05, ** denotes p < 0.005. (C) The 
potential interaction between QD394 and GPX4 was determined by cellular thermal shift assay. Detailed procedures 
are described in the methods section. QD394 decreased the melting temperature of GPX4 protein by quantification 
using Image J and GraphPad Prism. QD394 was tested at 100 μM for 1 h. RT: room temperature, around 21 °C. (D) 
Knockdown of GPX4 significantly reduced cytotoxicity of QD394. siNC: samples treated with scramble siRNA; 
siGPX4: samples treated with GPX4 siRNA. * denotes p < 0.05. Cells were immunoblotted with GPX4 antibody to 
validate GPX4 knockdown. (E) RSL3 inhibited colony formation in pancreatic cancer cells, and QD394 rescued its 
effect. 
 
 
 
 
 
 
 
 51 
 
Figure III-S3. Combination studies between QD394, napabucasin, and cell death inhibitors in MIA PaCa-2 cells.  
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Figure III-S4. QD394 and QD394-Me reduced the melting temperature of GPX4 in PANC-1 cells. (A) QD394. (B) 
QD394-Me. RT: around 21 °C. 
 
QD394 interferes with mitochondrial gene expression and RNA catabolic process 
To further investigate the Bru-seq results at the protein level, we performed proteomics 
and measured the changes caused by QD394. QD394 increased the expression of 84 proteins and 
decreased the expression of 146 proteins by at least 1.5-fold (FDR < 0.05) after 24 h treatment in 
MIA PaCa-2 cells with duplicates. There are 17 upregulated and 35 downregulated 
genes/proteins in common between the proteomics and Bru-seq analysis (Figure III-4A). In the 
STRING analysis 13, the 17 proteins with increased expression were involved in the response to 
endoplasmic reticulum (ER) stress, the unfolded protein response, and the transcription from 
RNA polymerase II promoter related to oxidative stress (Table III-3). Furthermore, the 35 
proteins with decreased protein expression had a close connection with mitochondrial genes, 
mitochondrial translation regulation, and cellular metabolic processes (Table III-4, Figure III-
4B). QD394 reduced expression of proteins involved in mitochondrial RNA catabolic processes, 
which is consistent with the Bru-seq GSEA analysis showing that QD394 downregulated the 
KEGG RNA degradation gene set. We observed that LRPPRC and PNPT1 are involved in many 
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of the biological processes downregulated by QD394 (Table III-4). LRPPRC (Leucine Rich 
Pentatricopeptide Repeat Containing) encodes a protein localized primarily to mitochondria, and 
it may regulate RNA metabolism and transcription in both nuclei and mitochondria. PNPT1 
(Polyribonucleotide Nucleotidyltransferase 1) encodes a mitochondrial intermembrane protein in 
the polynucleotide phosphorylase family comprised of phosphate-dependent 3’-to-5’ 
exoribonucleases implicated in RNA processing and degradation. More importantly, we 
discovered that high expression of both genes significantly correlated with reduced overall 
survival of pancreatic cancer patients in the TCGA PAAD dataset (Figure III-4C). In the 24 h 
proteomics experiment, QD394 reduced the expression of these two proteins (FDR < 0.05); 
additionally, QD394 significantly decreased their expression at 4 h (Figure III-4D). Napabucasin 
also decreased the protein expression of these two genes at 4 h, while H2O2 did not. We 
combined NAC and dicoumarol (an NQO1 inhibitor) with QD394 and napabucasin to assess the 
effects on the expression of LRPPRC and PNPT1 (Figure III-S5). NAC did not affect the 
downregulation of these two proteins caused by QD394 and napabucasin; however, dicoumarol 
blocked the reduction, indicating that NQO1 is a potential regulator in this process. Therefore, in 
PANC-1 cells, which have little intrinsic NQO1 expression, we did not observe the 
downregulation of LRPPRC and PNPT1 proteins by QD394 and napabucasin (Figure III-S5). 
    Besides these two mitochondrial proteins related to RNA processing, QD394 also 
reduced the expression of other mitochondrial proteins in the proteomics study, substantiating its 
possible role in affecting mitochondrial function (Figure III-4E). Overall, QD394 downregulated 
mitochondrial proteins, including LRPPRC and PNPT1 in both Bru-seq and proteomics 
experiments. 
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Figure III-4. Common genes/proteins between Bru-seq and proteomics analysis reveal that QD394 interferes with 
mitochondrial gene expression and RNA catabolic process. (A) Venn diagrams of upregulated and downregulated 
genes/proteins between Bru-seq (fold change over 2) and proteomics (fold change over 1.5) analysis. (B) STRING 
analysis of 35 downregulated genes/proteins in common between Bru-seq and proteomics studies. Red circle 
highlights the genes involved in mitochondrial gene and translation regulation. Blue circle indicates the genes 
associated with the oxidation reduction process. (C) LRPPRC and PNPT1 are significantly related to the overall 
survival of pancreatic adenocarcinoma patients in TCGA dataset. (D) QD394 decreased the protein expression of 
LRPPRC and PNPT1 in MIA PaCa-2 cells. QD394 and napabucasin were tested at 3 × IC50 for 1 h and 4 h. QD394 
was tested at 2 × IC50 for 24 h. H2O2 was used at 150 μM. * denotes p < 0.05, ** denotes p < 0.005, *** denotes p < 
0.0005. (E) The expression of mitochondrial proteins decreased in the QD394-treated MIA PaCa-2 cells. 
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Table III-3. STRING analysis of 17 upregulated genes/proteins in common between Bru-seq and proteomics. 
Biological process GO terms are ranked by FDR.  
Biological Process (GO) Count FDR Matching proteins 
response to endoplasmic reticulum 
stress 
5 0.0018 ASNS,CTH,HSPA5,PPP1R15A, 
SESN2 
cellular response to glucose starvation 3 0.003 ASNS,HSPA5,SESN2 
negative regulation of response to 
stimulus 
8 0.0055 CD55,CTH,HMOX1,HSPA5, 
PPP1R15A,RIOK3,SERPINE1, 
SESN2 
negative regulation of immune effector 
process 
3 0.0078 CD55,HMOX1,RIOK3 
response to stress 10 0.0078 ASNS,CD55,CTH,HMOX1, 
HSPA5,IFRD1,PPP1R15A, 
RIOK3, SERPINE1,SESN2 
negative regulation of signal 
transduction 
7 0.0078 CTH,HMOX1,HSPA5, 
PPP1R15A,RIOK3,SERPINE1,
SESN2 
endoplasmic reticulum unfolded 
protein response 
3 0.0078 ASNS,CTH,HSPA5 
cellular response to nutrient levels 4 0.0078 ASNS,HMOX1,HSPA5,SESN2 
PERK-mediated unfolded protein 
response 
2 0.0078 ASNS,HSPA5 
negative regulation of apoptotic 
process 
6 0.0078 ASNS,CBX4,CTH,HMOX1, 
HSPA5,SERPINE1 
regulation of translation in response to 
stress 
2 0.0078 PPP1R15A,SESN2 
regulation of transcription from RNA 
polymerase II promoter in response to 
stress 
3 0.0078 HMOX1,HSPA5,SESN2 
regulation of transcription from RNA 
polymerase II promoter in response to 
oxidative stress 
2 0.0078 HMOX1,SESN2 
negative regulation of cellular process 12 0.0078 ASNS,CBX4,CD55,CTH, 
HMOX1,HSPA5,IFRD1,JUND,
PPP1R15A,RIOK3,SERPINE1,
SESN2 
cellular response to chemical stimulus 9 0.0078 ASNS,CTH,HMOX1,HSPA5, 
JUND,RIOK3,SERPINE1, 
SESN2,ZFAND2A 
cellular response to arsenic-containing 
substance 
2 0.0078 HMOX1,ZFAND2A 
negative regulation of endoplasmic 
reticulum unfolded protein response 
2 0.0078 HSPA5,PPP1R15A 
regulation of PERK-mediated 
unfolded protein response 
2 0.0078 HSPA5,PPP1R15A 
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Table III-4. STRING analysis of 35 downregulated genes/proteins in common between Bru-seq and proteomics. 
Biological process GO terms are ranked by FDR. PNPT1 and LRPPRC are labeled in red.  
aspartate family amino acid 
biosynthetic process 
2 0.0079 ASNS,CTH 
response to organic substance 9 0.0082 ASNS,CTH,HMOX1,HSPA5, 
JUND,PLIN2,RIOK3, 
SERPINE1,SESN2 
Biological Process (GO) Count FDR Matching proteins 
mitochondrial gene 
expression 
8 1.04E-07 MRPL19,MRPS25,MRPS27,MRPS35,MRPS9,
PNPT1,PTCD3,TSFM 
mitochondrial 
translational elongation 
7 1.16E-07 MRPL19,MRPS25,MRPS27,MRPS35,MRPS9,
PTCD3,TSFM 
mitochondrial 
translational termination 
6 2.58E-06 MRPL19,MRPS25,MRPS27,MRPS35,MRPS9,
PTCD3 
regulation of 
mitochondrial translation 
4 1.74E-05 FASTKD2,LRPPRC,MRPS27,TSFM 
cellular respiration 6 2.73E-05 ACO2,FASTKD2,NDUFS1,NDUFS4,SDHC, 
SUCLG1 
oxidation-reduction 
process 
10 0.0002 ACO2,AUH,FASTKD2,HADHA,NDUFS1, 
NDUFS4,PEX13,SDHC,SUCLG1,TYW1 
generation of precursor 
metabolites and energy 
7 0.00026 ACO2,FASTKD2,FECH,NDUFS1,NDUFS4, 
SDHC,SUCLG1 
metabolic process 30 0.00029 ACO2,AUH,FAM120B,FAM20B,FASTKD2, 
FECH,HADHA,LRPPRC,MCCC1,MRPL19, 
MRPS25,MRPS27,MRPS35,MRPS9,NCOA6,
NDUFS1,NDUFS4,NFU1,PEX13,PNPT1, 
PTCD3,SATB1,SDHC,SPG7,SUCLG1, 
TFAP2A,TSFM,TYW1,XPNPEP3,ZNF318 
peptide metabolic process 7 0.001 MRPL19,MRPS25,MRPS27,MRPS35,MRPS9,
PTCD3,TSFM 
cellular metabolic 
process 
28 0.001 ACO2,AUH,FAM120B,FAM20B,FASTKD2, 
FECH,HADHA,LRPPRC,MCCC1,MRPL19, 
MRPS25,MRPS27,MRPS35,MRPS9,NCOA6,
NDUFS1,NDUFS4,NFU1,PEX13,PNPT1, 
PTCD3,SATB1,SDHC,SUCLG1,TFAP2A, 
TSFM,TYW1,ZNF318 
tricarboxylic acid cycle 3 0.0012 ACO2,SDHC,SUCLG1 
cellular amide metabolic 
process 
8 0.0012 MCCC1,MRPL19,MRPS25,MRPS27, 
MRPS35,MRPS9,PTCD3,TSFM 
protein-containing 
complex subunit 
organization 
12 0.0012 ATPAF1,FASTKD2,MCCC1,MRPL19, 
MRPS25,MRPS27,MRPS35,MRPS9,NDUFS1,
NDUFS4,PNPT1,PTCD3 
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Figure III-S5. Combination of NAC, dicoumarol (DIC) with QD394, QD394-Me, napabucasin (napa) and H2O2 in 
probing LRPPRC and PNPT1 in pancreatic cancer cells. QD394, QD394-Me and napabucasin were tested at 3 × 
IC50 for 4 h. H2O2 was tested at 200 μM. NAC (3 mM) and DIC (20 μM) were added 1 h before compound 
treatments. (A, B) MIA PaCa-2. (C) PANC-1. (D) BxPC-3. 
 
 
 
regulation of 
mitochondrial RNA 
catabolic process 
2 0.0014 LRPPRC,PNPT1 
citrate metabolic process 3 0.0014 ACO2,SDHC,SUCLG1 
leucine catabolic process 2 0.0016 AUH,MCCC1 
organic substance 
metabolic process 
28 0.0016 ACO2,AUH,FAM120B,FASTKD2,FECH, 
HADHA,LRPPRC,MCCC1,MRPL19, 
MRPS25,MRPS27,MRPS35,MRPS9,NCOA6,
NDUFS1,NDUFS4,PEX13,PNPT1,PTCD3, 
SATB1,SDHC,SPG7,SUCLG1,TFAP2A, 
TSFM,TYW1,XPNPEP3,ZNF318 
leucine metabolic process 2 0.0026 AUH,MCCC1 
cellular nitrogen 
compound metabolic 
process 
20 0.0026 FAM120B,FECH,LRPPRC,MCCC1,MRPL19,
MRPS25,MRPS27,MRPS35,MRPS9,NCOA6,
NDUFS1,NDUFS4,PNPT1,PTCD3,SATB1, 
SDHC,TFAP2A,TSFM,TYW1,ZNF318 
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QD394 is synergistic with napabucasin and select FDA-approved drugs 
ROS inducers sensitize cancer cells to standard-of-care chemotherapy and radiation 14. 
QD394 and napabucasin showed synergism in the colony formation assay in both MIA PaCa-2 
and PANC-1 cells (Figure III-5A, S6), suggesting the potential development of combination 
studies between redox modulator QD394 and cancer stemness inhibitors such as napabucasin. 
We next tested whether QD394 would act in synergy with the ROS inducer arsenic trioxide 
(As2O3), which is approved to treat acute promyelocytic leukemia (APL). As2O3 have been 
shown to reduce protein expression of Bcl-2, increase cellular ROS, induce permeability 
transition pore complex (PTPC) opening, and impair cell proliferation and apoptosis 15. QD394 
sensitized cells to As2O3, implying the synergistic effects between QD394 and different redox 
modulators (Figure III-5B). Since QD394 caused DNA damage, we assessed the synergy 
between QD394 and compounds regulating DNA repair. Olaparib, a poly(ADP-ribose) 
polymerase (PARP) inhibitor, is an FDA-approved drug to treat breast, ovarian, and pancreatic 
cancer 16. Combination of QD394 and olaparib resulted in synergistic effects in the colony 
formation assay (Figure III-5C). Cumulatively, QD394 is synergistic with cancer stemness 
inhibitors, other redox modulators, and PARP inhibitors. 
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Figure III-5. QD394 is synergistic with select FDA-approved drugs in pancreatic cancer cells. Napabucasin (A), 
As2O3 (B), and Olaparib (C) were added 1 h before QD394. Cells were treated with compounds for 24 h. 
 
 
 
Figure III-S6. Combination of QD394 and napabucasin in PANC-1 cells.  
 
QD394-Me shows improved plasma stability and reduced toxicity compared to QD394 in 
mice 
We determined the stability of QD394 in mouse liver microsomes and plasma. The half-
life of QD394 is over 60 minutes in mouse liver microsomes, yet only six minutes in mouse 
plasma, indicating it has good microsomal stability but poor metabolic stability in plasma (Table 
III-5). We then determined its potential metabolites in mouse plasma to better guide the design 
of more metabolically stable derivatives (Figure III-6A). M1 and M2 metabolites have hydroxyl 
groups on the rings, and M3 and M4 metabolites are produced through a Michael addition. We 
then synthesized QD394-Me with a methyl group to block Michael addition (Figure III-6B). 
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This improved the plasma stability of QD394 from six minutes to over two hours. Next, we 
estimated the PK characteristics of QD394 and QD394-Me in CD-1 mice following 
intraperitoneal injection (IP, 10 mg/kg), oral administration (PO, 20 mg/kg), or intravenous (IV, 
10 mg/kg) injection. Plasma concentration of both QD394 and QD394-Me rapidly decreased 
within the first two hours (Figure III-S7). Notably, two out of three mice administered with 
QD394 via IV injection died likely due to systemic toxicity, while all three mice that received IV 
injections of QD394-Me survived throughout the study (Table III-5). Therefore, QD394-Me 
appears to be less toxic and more tolerable in mice compared to QD394.  
    To understand why the concentration of QD394-Me rapidly decreased in the plasma, we 
assessed tissue distribution of QD394-Me administered via IV and PO in mice. After one-hour 
treatment, colon had the highest concentration of QD394-Me, although this was relatively low 
compared to the dosage (Colon: around 0.3 mg/kg, PO: 20 mg/kg, IV: 10 mg/kg) (Table III-S2). 
Besides distribution to organs, we identified potential metabolites of QD394-Me. The major 
metabolite of QD394-Me contains two hydroxyl groups on the right benzene or piperazine ring 
(Figure III-S8). As early as 15 min, we observed the major metabolite in the plasma; however, 
both the parent and metabolite compounds were distributed and excreted quickly over time 
(Figure III-S8). 
    In terms of tissue distribution results and similar cytotoxicity of QD394 in HCT116 
colon cancer cell lines (IC50 = 0.7 μM), we conducted a preliminary animal study in immuno-
competent Balb/c mice using mouse colon cancer cell line CT-26. Three out of five mice 
displayed tumor shrinkage in the QD394-Me IV (10 mg/kg) and QD394 IP (20 mg/kg) treatment 
groups; however, we did not observe significant differences in the tumor sizes between control 
and treatment groups due to high variance (Figure III-S9). A more robust evaluation of their 
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efficacy in pancreatic cancer mouse models and potential combination studies with FDA-
approved drugs could be further explored. 
 
Table III-5. PK optimization of QD394. Microsomal stability, plasma stability, and PK studies were performed to 
evaluate the PK profiles of QD394 and its analog QD394-Me. Key parameters for each experiment are listed. 
 
Compound Microsomal 
stability T1/2 (min) 
Plasma stability 
 T1/2 (min)  
Concentration at 7 h in mouse 
plasma (ng/mL) 
mouse mouse human IP (n=2) PO (n=2) IV (n=3) 
QD394 > 60 6 NA 5.0, 4.5 23.3, 25.8 2 out of 3 
mice died 
QD394-Me 44.6 > 120 > 120 6.7, 1.1 4.2, 3.4 3.4 ± 1.2 
 
Table III-S1. Tissue distribution of QD394-Me in mouse. IV 10 mg/kg, PO 20 mg/kg, 1 h.  
 
 1h 
Concentrations (ng/mL or ng/g) 
PO 20mg/kg IV 10mg/kg 
Plasma 52 25.8 
Blood 209 86.4 
Skin 33.1 20.45 
Bone 13.7 36.5 
Lung 22.6 35.9 
Pancreas 28.4 55 
Spleen 40 249.5 
Kidney 126.5 142.5 
Colon 339 277.5 
Liver 51 31.15 
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Figure III-6. Pharmacokinetics optimization of QD394 leads to QD394-Me with better stability in mouse plasma, 
and QD394-Me has a similar cellular profile as QD394. (A) Potential metabolites of QD394 in mouse plasma. The 
hydroxyl groups could be on either ring in the circle. (B) Structures of QD394 and QD394-Me. (C) QD394-Me 
increased cellular ROS level, and NAC reduced the induction of ROS at 30 min. ** denotes p < 0.005, *** denotes 
p < 0.0005. (D) QD394-Me significantly increased lipid peroxidation in MIA PaCa-2 cells. (E) QD394-Me 
destabilized GPX4 protein in MIA PaCa-2 cells. QD394-Me was tested at 100 μM. (F) The cytotoxicity of QD394-
Me was significantly reduced in the GPX4-knockdown MIA PaCa-2 cells. siNC: samples treated with scramble 
siRNA; siGPX4: samples treated with GPX4 siRNA. (G) QD394-Me reduced the protein expression of LRPPRC 
and PNPT1 significantly at 4 h in MIA PaCa-2 cells. QD394-Me was tested at 3 × IC50 for 1 h and 4 h, and 2 × 
IC50 for 24 h. * denotes p < 0.05, ** denotes p < 0.005. (H) Select enriched gene sets of QD394-Me in MIA PaCa-
2 Bru-seq samples.  
 
 
Figure III-S7. Plasma concentration of QD394 and QD394-Me administered via IP, PO, or IV in CD-1 mice. 
 
 
 
 
 
 
 
 64 
 
 
Figure III-S8. Major metabolite of QD394-Me in mouse plasma and its abundance profiles administered via IV or 
PO in mice. Two hydroxyl groups could be on either ring within the circle. 
 
 
 
Figure III-S9. In vivo study with female Balb/c mice implanted subcutaneously with CT-26 cells. QD394 (QD) was 
dosed at 10 mg/kg IP, and QD394-Me (QDMe) was dosed 3 times weekly at 20 mg/kg IV. Five mice were in each 
group. 
 
 
QD394-Me and QD394 share similar cell death mechanisms 
QD394-Me and QD394 show similar cytotoxicity in PANC-1 and BxPC-3 cells, while 
QD394-Me is less potent than QD394 in MIA PaCa-2 cells (Table III-1). QD394-Me also 
significantly increased cellular ROS in MIA PaCa-2 cells, and NAC blocked the induction of 
ROS (Figure III-6C). Similar to QD394, QD394-Me increased lipid ROS significantly in a dose-
dependent manner (Figure III-6D). QD394-Me destabilized GPX4 protein in pancreatic cancer 
cells in the CETSA experiments (Figure III-6E, S4), and its cytotoxicity was significantly 
reduced in the GPX4-knockdown experiments (Figure III-6F, Table III-S2). Moreover, QD394-
Me significantly decreased protein expression of LRPPRC and PNPT1 at 4 h, consistent with 
QD394 in MIA PaCa-2 cells (Figure III-6G). Therefore, QD394-Me shows a similar mechanism 
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of action to QD394 in pancreatic cancer cells but has improved plasma stability and less in vivo 
toxicity.  
Bru-seq analysis of QD394-Me 
We tested QD394-Me in MIA PaCa-2 using Bru-seq experiments. QD394-Me induced 
hallmark gene sets related to TNF signaling and hypoxia, which is similar to QD394. 
Additionally, QD394-Me increased upfolded protein response, suggesting potential ER stress 
(Figure III-6H). QD394-Me also induced ROS pathway and JAK/STAT3 signaling hallmark 
gene sets, supporting its ROS-inducing capability and STAT3-targeting effects. KEGG pathways 
related to proteasome, ribosome and spliceosome were enriched by QD394-Me, indicating its 
downstream effects on protein and transcript regulation (Figure III-6H). There are no common 
downregulated enriched gene sets between QD394 and QD394-Me Bru-seq samples, and this 
could be because that QD394-Me only significantly stimulated very few decreased gene sets at 
3×IC50 concentration in MIA PaCa-2. 
 
Table III-S2. Cytotoxicity of QD394, QD394-Me, and napabucasin in GPX4-knockdown PANC-1 and BxPC-3 
cells. siNC: samples treated with scramble siRNA; siGPX4: samples treated with GPX4 siRNA. 
 
IC50 (μM)  
PANC-1 BxPC-3 
siNC siGPX4 siNC siGPX4 
QD394   0.362   1.064   0.715   1.292 
QD394-Me   2.734   6.74   3.55   4.649 
Napa   1.159   3.143   1.041   1.72 
 
Discussion 
    ROS induction alters the activity of multiple transcription factors, including STAT3, NF-
κB, and hypoxia-inducible factor-1α (HIF-1A) 17. STAT3 signaling is downstream of MAPK, 
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JAK, and Src pathways. Redox modulation can inactivate these kinases leading to either 
activation or inhibition of STAT3 signaling, depending on cellular context and duration of ROS 
generation 18. TNFA signaling and hypoxia hallmark gene sets were upregulated by QD394 and 
napabucasin. TNFA/TNF are important cytokines for maintaining cellular homeostasis and 
mediating the activation of NF-κB, which in turn regulates downstream prosurvival genes, 
MAPK signaling, and cell death in cancers and inflammatory diseases 19,20. The transcription 
factor HIF-1A is activated by hypoxic conditions and responds to accumulated ROS via NF-κB 
activation 21,22. ROS induction by QD394 and napabucasin can trigger these signaling pathways. 
Napabucasin is a cancer stemness inhibitor that reduces the proliferation, invasion, and stemness 
of cancer cells 23,24. Napabucasin is bioactivated by NQO1 and generates ROS to induce DNA 
damage and cell death 25. In this study, we report that necrostatin-1 rescued napabucasin-
mediated cell death, suggesting that napabucasin induces necroptotic cell death in pancreatic 
cancer cells. However, QD394 did not cause necroptosis, but iron-, ROS-dependent, and GPX4-
mediated ferroptosis (Figure III-7) 26,27. 
Liproxstatin-1 inhibits ferroptosis induced by erastin, BSO and RSL3 in vitro, and it 
prevents ferroptosis and ROS accumulation in GPX4 knockout cells both in vitro and in vivo 28,29. 
Ferrostatin-1 is a first-generation ferroptosis inhibitor that rescues cell death caused by erastin 
and RSL3 1,30. Additionally, both compounds are effective radical-trapping antioxidants in the 
lipid bilayers 30. However, ferrostatin-1 did not prevent H2O2-induced necrosis, although 
ferroptosis is defined as a necrotic-like cell death 1. The fact that QD394 induces ROS may 
explain why ferrostatin-1 did not rescue QD394-induced cell death. Although ferrostatin-1 
blocked lipid peroxidation and ferroptosis, QD394 could cause ROS-involved DNA damage and 
necrotic cell death (Figure III-7). Therefore, we suggest that a combination of cell death 
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pathways are induced by QD394 and QD394-Me, but ferroptosis is an essential part since GPX4 
protein expression regulates the cytotoxicity of QD394 and QD394-Me. Interestingly, we 
determined potential interactions between QD394, QD394-Me, and GPX4 in the cells, but the 
detailed binding site requires further investigation. 
    LRPPRC and PNPT1 are closely related to mitochondrial translation and RNA catabolic 
processes in different diseases 31–34. LRPPRC deficiency alters mitochondrial electron transport 
chain, mitochondrial permeability, and transmembrane ROS diffusion 35. PNPT1 regulates the 
correct maturation of mitochondrial ND6 transcripts and efficient mitochondrial RNA 
degradation 33,34. Both proteins are involved in mitochondrial function and negatively associated 
with the survival of pancreatic adenocarcinoma patients. Our redox modulators, QD394 and 
QD394-Me, decreased the expression of these two proteins, which thus could be used as 
potential pharmacodynamic biomarkers in pancreatic cancer (Figure III-7). Meanwhile, further 
understanding of the connection between overexpression of these two genes and pancreatic 
cancer is needed and may lead to novel therapeutics. 
Conclusions 
In this study, we developed a novel redox modulator QD394 and explored its 
mechanisms of action in pancreatic cancer cells. QD394 shares a highly similar transcriptomic 
profile to napabucasin, inhibits STAT3 phosphorylation, increases ROS levels, and induces 
DNA damage. However, while napabucasin causes necroptosis, QD394 induces an iron-, ROS-
dependent, and GPX4-mediated cell death. One essential cell death mechanism of QD394 is 
ferroptosis, since QD394 increases lipid peroxidation, destabilizes GPX4 protein, and its 
cytotoxicity is dependent on GPX4. Bru-seq and proteomics analysis reveal that QD394 
decreases both nascent transcripts and protein expression of LRPPRC and PNPT1. Furthermore, 
 
 
 
 
 
 
 68 
QD394 acts in synergy with several FDA-approved drugs, suggesting its potential utility to 
overcome drug resistance. A PK-guided optimization campaign resulted in QD394-Me with 
improved mouse plasma stability and less systemic toxicity in mice. 
 
 
Figure III-7. Summarized working mechanisms of QD394 and QD394-Me in pancreatic cancer cells. QD394 and 
QD394-Me increase cellular ROS level, induce DNA damage, decrease mitochondrial proteins, and promote 
accumulation of lipid ROS. They oxidize GSH to GSSG and destabilize GPX4 in the cells. Their cytotoxicity is 
dependent on iron, ROS, and GPX4 expression. Ferroptosis and necrosis are potentially involved in their cell death 
mechanisms. 
 
Methods 
Chemical compounds. Stock solutions of QD compounds and napabucasin were made in 
dimethylsulfoxide (DMSO) at 10 mM and were stored at -20 °C. QD compounds were 
synthesized in Dr. Mario Sechi’s Lab at the University of Sassari. Napabucasin was purchased 
from Medchem Express. N-acetyl cysteine (Sigma) and deferoxamine mesylate salt (Sigma) 
were dissolved in ultrapure water (Gibco). Z-VAD (MedChemExpress), necrostatin-1 
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(Selleckchem), RSL3 (Cayman Chemical), deferasirox (Cayman Chemical), liproxstatin-1 
(Cayman Chemical), ferrostatin-1 (Cayman Chemical), chloroquine phosphate (LKT LABS), 
olaparib (MedChemExpress), 3-Methyladenine (Cayman Chemical), and N-phenylmaleimide 
(Oakwood Chemical) were dissolved in DMSO. 
Cell lines and cell culture. Pancreatic cancer cell lines (MIA PaCa-2, PANC-1, and BxPC-3) 
were purchased from ATCC. All cell lines were maintained in RPMI 1640 (Gibco) containing 
10% FBS (Gibco) at 37 °C in a humidified atmosphere of 5% CO2. All cell lines were in culture 
under 35 passages and determined to be free of mycoplasma contamination using Plasmo Test 
(InvivoGen, San Diego, CA).  
MTT assay. Cytotoxicity was determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide (MTT) assay. Cells were seeded in 96-well tissue culture plates 
and allowed overnight attachment. Subsequently, cells were treated with compounds or DMSO 
for 72 h. MTT solution (0.3 mg/mL) was added to each well for 3 h in the incubator. After 
removal of the media, DMSO was added, and the plates were shaken for 15 min before 
measuring the absorbance at a wavelength of 570 nm using a microplate reader (Molecular 
Devices). IC50 values were calculated using GraphPad Prism. 
Colony Formation Assay. Cells were seeded in 96-well tissue culture plates at 300 cells (MIA 
PaCa-2) or 600 cells (PANC-1 and BxPC-3) per well. After overnight attachment, cells were 
treated with compounds continuously. Cell death inhibitors or signaling pathway inhibitors were 
added 1 h prior to compound treatment. Plates were incubated for 7-9 days until cells in the 
control wells became 80-90% confluent. Media was removed, and cells were stained with a 0.05% 
crystal violet solution for 30 min. Cells were then washed with ddH2O to remove excess stain, 
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and the plates were imaged using Odyssey Imaging Systems (LI-COR Biosciences) after 
overnight drying. 
ROS measurement. Cells were seeded in 96-well flat clear-bottom black tissue-culture plates 
(Corning #3603) at a density of 1.8 × 104 cells per well. After overnight attachment, cells were 
stained with CM-H2DCFDA dye (10 μM, Thermo Fisher, C6827) in HBSS for 40 min at 37 °C. 
Cells were washed with pre-warmed DPBS (Gibco) twice, and 80 µL HBSS was added. 
Compounds were added in HBSS at designated concentrations. Fluorescent signal was measured 
using a CLARIO Star plate reader (Ex: 483-15 nm; Em: 530-20 nm; BMG LABTECH). 
GSH/GSSG-Glo assay. GSH/GSSG-Glo assay kit (Promega) was used to determine the 
GSH/GSSG ratio in cells with drugs or DMSO. 15,000 - 20,000 cells per well were seeded into 
solid opaque 96-well tissue culture plates (Falcon). After overnight attachment and compound 
treatment, medium was removed, and cells were lysed with 50 μL of Total or Oxidized 
Glutathione Reagent per well. The plate was shaken for 5 minutes, and 50 μL fresh Luciferin 
Generation Reagent was added to each well. After 30-min incubation at room temperature, 100 
μL Luciferin Detection Reagent was added. Luminescence was detected using a CLARIOstar 
plate reader (BMG LABTECH) after 15-min equilibration. GSH/GSSG ratio was calculated with 
net RLU, using the formula: (net vehicle total glutathione RLU – net vehicle GSSG RLU)/(net 
vehicle GSSG RLU/2). 
Bru-seq experiments and analysis. Nascent RNA Bru-seq experiments were performed as 
previously reported 6. Briefly, 2 × 106 cells were seeded in 10 cm dishes in duplicates. After 
overnight attachment, cells were treated with compounds (3 × IC50) for 4 h. Cells were added 
with bromouridine at a final concentration of 2 mM and incubated at 37 °C for the last 30 min of 
the drug treatments. Cells were then collected and lysed in TRIzol, and total RNA was isolated. 
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The bromouridine-containing RNAs were captured using anti-BrdU antibodies conjugated to 
magnetic beads and converted to cDNA libraries (Illumina TrueSeq), which were sent for deep 
sequencing at the University of Michigan Sequencing Core. Sequencing reads were mapped to 
the hg38 reference genome, and DESeq2 was used to determine differentially expressed genes. 
The shrunkenLFC (shrunken log2FoldChange) was calculated from DESeq2. We used 
shurnkenLFC for the heatmap and GSEA analysis. Downstream signaling pathways were 
identified using GSEA. Heatmaps and statistics were generated using the R programming 
language. 
Immunoblot. Cells were seeded in 6-well tissue culture plates at 3.5 × 105 cells per well. After 
compound treatments, cells were washed with DPBS (Gibco) and lysed with RIPA buffer 
containing 1× protease inhibitor (Sigma) and 1× phosphatase inhibitor (Sigma). Cell lysates 
were sonicated before centrifugation at 14, 000 rpm for 10 min at 4 °C, and supernatant was 
collected for BCA protein assay (Thermo Scientific). 25 μg proteins from each sample was 
resolved on 10% SDS polyacrylamide gels and electrotransferred to PVDF membranes (Trans-
Blot® Turbo™ RTA Mini PVDF Transfer Kit, BIO-RAD). After blocking with 5% milk in 1× 
TBS for 1 h at room temperature, membranes were probed with primary antibodies (1:500-
1:1000) in 5% milk in 1× TBST or 5% BSA in 1× TBST overnight at 4 °C. The membranes 
were then washed with TBST three times, and probed with anti-rabbit or anti-mouse secondary 
antibody (Dylight 800 4 × PEG conjugated; Thermo Scientific; 1:6000) for 1 h at room 
temperature. Membranes were imaged with Odyssey Imaging Systems (LI-COR Biosciences). 
Protein expression was quantified with ImageJ and normalized to loading controls. 
Lipid ROS measurement. MIA PaCa-2 cells were treated with compounds for the designated 
time before 10 μM C11-BODIPY (Thermo Fisher) was added, and cells were incubated for 30 
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min at 37 °C. Cells were washed with DPBS (Gibco) twice, and 100 μL HBSS was added before 
measurement using a CLARIOstar plate reader (BMG LABTECH). Plates were read with two 
filter sets; one at excitation/emission of 581/591 nm (Texas Red) for the reduced dye, and the 
other at excitation/emission of 488/510 nm (FITC) for the oxidized dye. The ratio of the 
emission fluorescence intensities at the Texas Red filter and FITC filter was calculated in 
Microsoft Excel, and p value was determined using unpaired Student’s t-test. 
Cellular Thermal Shift Assay (CETSA). Cells were seeded at 3 × 106 cells per 10 cm cell 
culture dish. After overnight attachment, 100 μM QD394, QD394-Me, or DMSO was added to 
the cells for 1 h. Cells were then trypsinized, washed with DPBS, and suspended in 650 μL 
DPBS. The suspensions were split into 100 μL aliquots, heated at indicated temperatures for 3 
minutes in the Veriti Thermal Cycler (Applied Biosystems), and incubated for 3 minutes at room 
temperature. Each aliquot was flash-frozen three times and spun at 12,000 rpm for 20 minutes at 
4 °C. Supernatants were collected, and 25 μL of each sample was loaded onto a 10% SDS 
polyacrylamide gel for immunoblot analysis using the protocol detailed above. 
siRNA knockdown of GPX4. GPX4 siRNA (s6110) and negative control siRNA (4390843) 
were purchased from Thermo Fisher. According to the manufacturer’s instructions, 3.5 × 105 
cells were seeded in 6-well tissue culture plates for overnight attachment. The siRNA 
transfection reagent complex was formed by combining 30 pmol siRNA in 150 μL Opti-MEM 
medium (Thermo Fisher) with 9 μL Lipofectamine RNAiMAX Reagent (Thermo Fisher) in 150 
μL Opti-MEM medium. After 15-min incubation, this complex was added to each well with 
fresh medium for 48 h. One half of these cells were harvested for immunoblot, and the other half 
were seeded for the 24 h MTT assay to determine the cytotoxicity of QD394, QD394-Me, and 
napabucasin. 
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Proteomics study. MIA PaCa-2 cells were treated with 1.2 μM QD394 or DMSO control for 24 
h before collecting the cell lysates in RIPA buffer. 75 µg proteins of each sample was sent to the 
Proteomics Core at the University of Michigan in duplicate. TMT10plex Mass Tag Labeling Kit 
(ThermoFisher) was used to quantify the proteins in each sample, and Abundance Ratio and log2 
Abundance Ratio were calculated as treatment over control. STRING analysis was performed 
using proteins with adjusted p values below 0.05. 
Survival analysis of LRPPRC and PNPT1. Patient sample RNASeq RSEM normalized gene 
expression values and related survival metadata were sourced from the TCGA GDAC Firehose 
36. When multiple samples were available for a given patient, barcodes were sorted 
alphabetically and the first was selected for analysis. TCGA disease patient samples were 
evaluated for reduced survivability by comparing survival outcomes for patients with high and 
low expression of LRPPRC and PNPT1. Thresholding for high and low expression patient 
populations was evaluated using five different quantile cutoffs: 95%, 90%, 75%, 50%, and 25%. 
A log-rank test statistic was calculated for each cutoff to compare the survival distributions of 
high and low expression patient populations with the null hypothesis that there was no difference 
in survival curves. Survival analysis was performed using the R statistical programming 
language. 
Microsomal stability test. The 10 mM stock solutions of QD394, QD394-Me, and verapamil 
(positive control) were prepared in DMSO. Solutions were diluted to 1 mM with acetonitrile and 
further diluted to 10 μM with 0.1 M phosphate buffer (3.3 mM MgCl2). NADPH (1 mg) was 
dissolved in 60 μL 0.1 M phosphate buffer (3.3 mM MgCl2). 330 μL 0.1 M phosphate buffer 
(3.3 mM MgCl2) and 40 μL 10 μM test compounds were added to 10 μL microsomes (20 
mg/mL). Data points were collected at 0, 5, 10, 15, 30, 45, and 60 min. Solutions were 
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centrifuged at 3500 g for 10 min to pellet precipitated proteins. The supernatant was used for 
LC/MS/MS analysis. Natural log peak area ratio (compound peak area / internal standard peak 
area) was plotted against time, and the gradient of the line was determined to calculate the half-
life (t1/2) of the test compound in microsomes. 
Plasma stability test. Pooled mouse plasma was stored at -80 °C prior to use. Compounds were 
dissolved in DMSO to obtain a concentration of 500 μM. 1 μL compound was added to 500 μL 
plasma. Samples were collected at time points of 0, 0.17, 0.5, 1, 2, and 4 h. The solution was 
centrifuged at 3500 g for 10 min to pellet precipitated proteins. The supernatant was used for 
LC-MS/MS analysis. Natural log peak area ratio (compound peak area / internal standard peak 
area) was plotted against time, and the gradient of the line was determined to calculate the half-
life (t1/2) of the test compound in plasma. 
PK study. QD394 and QD394-Me were administered by IP injection (10 mg/kg), oral PO (20 
mg/kg), or IV injection (10 mg/kg) to CD-1 mice. At the given time points (0.5, 2, 4, and 7 h), 
blood samples were collected using heparinized calibrated pipettes. Samples were centrifuged at 
15,000 rpm for 10 min. Subsequently, blood plasma was collected from the upper layer. The 
plasma was frozen at -80 ºC for LC-MS/MS analysis. 
Metabolite identification. QD394 and QD394-Me were incubated with mouse plasma under the 
same conditions as the plasma stability test. Samples were collected at 0.5 h to determine 
potential metabolites of QD394 or QD394-Me using LC-MS/MS analysis. Indicated metabolites 
were also measured in vivo after 1-hour QD394-Me treatment. 
Tissue distribution analysis. Mice were dosed with QD394 at 20 mg/kg PO and QD394-Me at 
10 mg/kg IV. After 1 h, indicated organs were collected for later analysis. Dissociation solvent 
was added at five-fold the tissue weight into each homogenization tube with beads for tissue 
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homogenization, and 30 μL homogenate was isolated for sample preparation. For calibration 
curve samples, 30 μL blank homogenate was mixed with 30 μL standard solution and 140 μL 
internal standard solution; for dosed samples, 30 μL homogenate was mixed with 30  μL blank 
acetonitrile and 140 μL internal standard solution. Samples were vortexed and centrifuged at 
3500 g for 10 min, and the supernatant was isolated for LC-MS analysis. 
Mice study. Female Balb/c mice were purchased from Envigo. At the time of implantation, all 
mice were aged 5-6 weeks. Mice were implanted subcutaneously in the right flank with 1 × 106 
CT-26 cells in 100 µL DPBS. Seven days after implantation, mice were randomized into groups 
(n = 5) with mean tumor volumes ranging from 97 to 117 mm3. The negative control group was 
dosed daily in the intraperitoneal cavity (IP) with the same vehicle used for QD394. QD394 was 
dosed at 10 mg/kg IP, and QD394-Me was dosed 3 times weekly intravenously (IV) at 20 mg/kg. 
After 17 days of dosing, four hours post-dose, negative control and treated groups were 
euthanized by CO2 asphyxiation followed by cervical dislocation. The end of the study was 
chosen as the first day that any mouse reached humane euthanasia criteria determined by the 
animal use protocol. 
Statistical analysis. For the Bru-seq analysis, Pearson correlation and p value were calculated 
using function cor.test() in R (version 3.3.2). Significance levels for assays and immunoblots 
were calculated using unpaired Student's t-test in Microsoft Excel. Results were shown as mean 
± standard deviation from at least three independent experiments. 
  
Author contributions 
Shuai Hu is the primary author. Mario Sechi’s lab synthesized the QD analogs. Mats 
Ljungman’s lab performed the Bru-seq experiments. Duxin Sun’s lab assisted the PK studies. 
 
 
 
 
 
 
 76 
Sean McCann conducted the animal studies. Armand Bankhead III made Figure II-4C. Nouri 
Neamati is the corresponding author. 
 
References 
1. Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 
1060–1072 (2012). 
2. Stockwell, B. R. et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, 
Redox Biology, and Disease. Cell 171, 273–285 (2017). 
3. Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the 
Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25, 486–541 (2018). 
4. Mou, Y. et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. 
J. Hematol. Oncol. 12, 34 (2019). 
5. Ye, L. F. et al. Radiation-Induced Lipid Peroxidation Triggers Ferroptosis and Synergizes 
with Ferroptosis Inducers. ACS Chem. Biol. 15, 469–484 (2020). 
6. Paulsen, M. T. et al. Use of Bru-Seq and BruChase-Seq for genome-wide assessment of the 
synthesis and stability of RNA. Methods 67, 45–54 (2014). 
7. Blaser, H., Dostert, C., Mak, T. W. & Brenner, D. TNF and ROS Crosstalk in 
Inflammation. Trends Cell Biol. 26, 249–261 (2016). 
8. Nishigori, C., Hattori, Y. & Toyokuni, S. Role of Reactive Oxygen Species in Skin 
Carcinogenesis. Antioxidants & Redox Signaling vol. 6 561–570 (2004). 
9. Rodust, P. M., Stockfleth, E., Ulrich, C., Leverkus, M. & Eberle, J. UV-induced squamous 
cell carcinoma--a role for antiapoptotic signalling pathways. Br. J. Dermatol. 161 Suppl 3, 
107–115 (2009). 
10. Görlach, A. et al. Reactive oxygen species, nutrition, hypoxia and diseases: Problems 
solved? Redox Biol 6, 372–385 (2015). 
11. Tafani, M. et al. The Interplay of Reactive Oxygen Species, Hypoxia, Inflammation, and 
Sirtuins in Cancer Initiation and Progression. Oxid. Med. Cell. Longev. 2016, 3907147 
(2016). 
12. Stockwell, B. R. Ferroptosis: Death by lipid peroxidation. Free Radical Biology and 
Medicine vol. 120 S7 (2018). 
13. Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased 
coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic 
Acids Res. 47, D607–D613 (2019). 
14. Gupta, S. C. et al. Upsides and downsides of reactive oxygen species for cancer: the roles 
of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid. Redox 
Signal. 16, 1295–1322 (2012). 
 
 
 
 
 
 
 77 
15. Carney, D. A. Arsenic trioxide mechanisms of action – looking beyond acute 
promyelocytic leukemia. Leukemia & Lymphoma vol. 49 1846–1851 (2008). 
16. Olaparib. National Cancer Institute https://www.cancer.gov/about-
cancer/treatment/drugs/olaparib (2014). 
17. Prasad, S., Gupta, S. C. & Tyagi, A. K. Reactive oxygen species (ROS) and cancer: Role of 
antioxidative nutraceuticals. Cancer Lett. 387, 95–105 (2017). 
18. Fang, B. Genetic Interactions of STAT3 and Anticancer Drug Development. Cancers  6, 
494–525 (2014). 
19. Annibaldi, A. & Meier, P. Checkpoints in TNF-Induced Cell Death: Implications in 
Inflammation and Cancer. Trends Mol. Med. 24, 49–65 (2018). 
20. Shen, J. et al. Anti-cancer therapy with TNFα and IFNγ: A comprehensive review. Cell 
Prolif. 51, e12441 (2018). 
21. Semenza, G. L. Defining the role of hypoxia-inducible factor 1 in cancer biology and 
therapeutics. Oncogene 29, 625–634 (2010). 
22. Bonello, S. et al. Reactive Oxygen Species Activate the HIF-1α Promoter Via a Functional 
NFκB Site. Arteriosclerosis, Thrombosis, and Vascular Biology vol. 27 755–761 (2007). 
23. Han, D. et al. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and 
stemness of glioblastoma cells. J. Exp. Clin. Cancer Res. 38, 289 (2019). 
24. Sugarman, R. et al. Pharmacokinetics and pharmacodynamics of new drugs for pancreatic 
cancer. Expert Opin. Drug Metab. Toxicol. 15, 541–552 (2019). 
25. Froeling, F. E. M. et al. Bioactivation of Napabucasin Triggers Reactive Oxygen Species-
Mediated Cancer Cell Death. Clin. Cancer Res. 25, 7162–7174 (2019). 
26. Pathania, D. et al. Design and discovery of novel quinazolinedione-based redox modulators 
as therapies for pancreatic cancer. Biochim. Biophys. Acta 1840, 332–343 (2014). 
27. Pathania, D., Kuang, Y., Sechi, M. & Neamati, N. Mechanisms underlying the cytotoxicity 
of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells. Br. 
J. Pharmacol. 172, 50–63 (2015). 
28. Friedmann Angeli, J. P. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute 
renal failure in mice. Nat. Cell Biol. 16, 1180–1191 (2014). 
29. Xie, Y. et al. Ferroptosis: process and function. Cell Death & Differentiation vol. 23 369–
379 (2016). 
30. Shah, R., Margison, K. & Pratt, D. A. The Potency of Diarylamine Radical-Trapping 
Antioxidants as Inhibitors of Ferroptosis Underscores the Role of Autoxidation in the 
Mechanism of Cell Death. ACS Chem. Biol. 12, 2538–2545 (2017). 
31. Zhou, W. et al. Proteasome-Independent Protein Knockdown by Small-Molecule Inhibitor 
for the Undruggable Lung Adenocarcinoma. J. Am. Chem. Soc. 141, 18492–18499 (2019). 
32. Cui, J., Wang, L., Ren, X., Zhang, Y. & Zhang, H. LRPPRC: A Multifunctional Protein 
Involved in Energy Metabolism and Human Disease. Front. Physiol. 10, 595 (2019). 
 
 
 
 
 
 
 78 
33. Matilainen, S. et al. Defective mitochondrial RNA processing due to PNPT1 variants 
causes Leigh syndrome. Hum. Mol. Genet. 26, 3352–3361 (2017). 
34. Liu, X. et al. PNPT1 Release from Mitochondria during Apoptosis Triggers Decay of 
Poly(A) RNAs. Cell 174, 187–201.e12 (2018). 
35. Cuillerier, A. et al. Loss of hepatic LRPPRC alters mitochondrial bioenergetics, regulation 
of permeability transition and trans-membrane ROS diffusion. Human Molecular Genetics 
vol. 26 3186–3201 (2017). 
36. Broad GDAC Firehose. https://gdac.broadinstitute.org/. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 79 
 
 
 
CHAPTER IV 
Identification and Characterization of Novel Mitochondrial Transcription Inhibitors 
Mitochondria are essential cellular organelles that serve as "powerhouses" to not only 
generate ATP through oxidative phosphorylation (OXPHOS), but also produce reactive oxygen 
species (ROS), control calcium signaling, and regulate cell cycle and differentiation 1–3. The 
mitochondria of cancer cells undergo extensive bioenergetic and biosynthetic reprogramming to 
facilitate proliferation, invasion, and metastasis 1–3. Increasing studies show that targeting 
mitochondria is an attractive anticancer therapy 4–7. Anticancer drug ditercalinium intercalates 
with the major groove of DNA and depletes mtDNA 8,9. An effective approach to generate small 
molecules targeting mitochondria is to conjugate a lipophilic cation, such as a 
triphenylphosphonium (TPP+) moiety, to the drug of interest 10,11. Previously, we developed a 
TPP-derivative of the nitrogen mustard chlorambucil (Figure IV-1), a DNA alkylating drug 
approved by the FDA for the treatment of chronic lymphocytic leukemia and lymphomas 12. 
This TPP-conjugated chlorambucil, named Mito-Chlor, selectively localizes to mitochondria, 
where it acts on mtDNA and causes cell cycle arrest and cell death 12. 
In this study, we show that Mito-Chlor, but not its precursor compound chlorambucil 
inhibits the transcription of the mitochondrial genome. Comparing Bru-seq data from other 
novel small molecules led to the identification of a new compound SQD1 featuring a 
styrylquinoline-5, 8-dione core as another mitochondrial transcription inhibitor. Quinones are 
 
 
 
 
 
 
 80 
widely distributed in natural products and several FDA approved drugs, such as doxorubicin, 
mitoxantrone, and apaziquone, have been extensively used for the treatment of multiple cancers 
(Figure IV-1). 
This study expanded current understanding of Mito-Chlor and identified it as a potent 
mitochondrial transcription inhibitor. A novel compound SQD1 sharing a similar transcriptomic 
profile with Mito-Chlor was also discovered and characterized in parallel with Mito-Chlor to 
further elucidate their mechanisms of action. 
 
Figure IV-1. The structures of SQD1, Mito-Chlor, chlorambucil and select anticancer agents with a quinone scaffold. 
 
Results and discussion 
Mito-Chlor and SQD1 inhibit the transcription of the mitochondrial genome 
The circular mitochondrial genome contains a guanine-rich heavy (H-strand) and a 
guanine-poor light strand (L-strand) 14. H-strand and L-strand are transcribed independently, 
controlled by the light-strand promoter (LSP), the heavy-strand promoter 1 (HSP1) and the 
heavy-strand promoter 2 (HSP2), which are located nearby in the displacement loop (D-loop), 
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the main non-coding region of the mtDNA 14. The H-strand encodes 12 mitochondrial proteins, 
such as ATP6 and CYB, while the L-strand only encodes ND6 (Figure IV-2A) 15. These proteins 
constitute essential subunits of the four mitochondrial respiratory chain complexes (I–IV). 
Mito-Chlor was shown to accumulate in mitochondria and act on mtDNA, setting it apart 
from its parent compound chlorambucil 12. In order to assess how Mito-Chlor affects 
mitochondrial genes, we used Bru-seq technique, a useful tool for interpreting the mechanism of 
action of novel agents 13,16. In the Bru-seq trace diagrams of mitochondrial transcripts, 
remarkably, after a 4-hour treatment in MIA PaCa-2 cells, Mito-Chlor inhibited transcription 
from the H-strand promoters, while having no detectable effect on transcription from the L-
strand promoter. In contrast, chlorambucil showed no inhibitory effect on either of the two 
strands (Figure IV-2B). In order to identify other small molecules with similar mechanism to 
Mito-Chlor, we performed a robust cluster analysis using a collection of over 100 in-house 
compounds analyzed by Bru-seq (not shown). This analysis led to the identification of a novel 
compound SQD1, featuring a unique styrylquinoline-5, 8-dione core (Figure IV-1). SQD1 shares 
a similar genome-wide transcription profile with Mito-Chlor, and interestingly, it is also found to 
block the transcription from the mitochondrial genome (Figure IV-2B). Additionally, H2O2 
inhibited mitochondrial transcription from the H-strand promoters in a dose-dependent manner 
(Figure IV-2B), indicating that ROS could cause mitochondrial transcription inhibition. 
We next conducted real-time PCR (RT-PCR) to detect the mRNA levels of mitochondrial 
genes located on both strands of the circular mtDNA (Figure IV-2C). MT-ND6 (mitochondrially 
encoded NADH: ubiquinone oxidoreductase core subunit 6) is the only protein-coding gene on 
the L-strand, and MT-ATP6 (mitochondrially encoded ATP synthase membrane subunit 6) and 
MT-CYB (mitochondrially encoded cytochrome B) are two protein-coding genes on the H-
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strand. Similar to the Bru-seq results, SQD1 significantly decreased the transcription of ATP6, 
CYB and ND6 genes, confirming that SQD1 inhibited mitochondrial transcription from all 
promoters (Figure IV-2B). Mito-Chlor reduced the steady-state level of ND6 transcripts 
expressed from the LSP promoter, which was not observed in the nascent RNA Bru-seq. 
Furthermore, Mito-Chlor decreased CYB transcription, not ATP6 transcription, although both 
genes are encoded by the H-strand (Figure IV-2C). In contrast to Mito-Chlor, chlorambucil did 
not inhibit the steady-state RNA levels of any of these three genes (Figure IV-2C). It is 
interesting to note the different results obtained with Bru-seq and RT-PCR of Mito-Chlor. A 
potential explanation for this is that RT-PCR quantifies the steady-state levels of total RNAs 
while Bru-seq only measures the newly synthesized RNA. 
The mitochondrial membrane potential (ΔΨm, MMP), generated by proton pumps, is 
critical for the physiological function of mitochondria. We next investigated whether these 
agents would affect MMP using tetramethylrhodamine methyl ester (TMRM), a cell-permeable 
dye that accumulates in active mitochondria with intact membrane potentials. After a 4-hour 
treatment, Mito-Chlor displayed significant decrease in the TMRM fluorescence level while 
SQD1 did not (Figure IV-2D). This result suggests that Mito-Chor also interfered with 
mitochondrial physiological function when inhibiting the mitochondrial transcription at 4 h, 
while SQD1 did not. 
In order to assess the effects of SQD1 and Mito-Chlor on mitochondrial function, we 
measured the ATP production in compound-treated MIA PaCa-2 cells in glucose and galactose 
medium (Figure IV-2E). In the glucose medium, mammalian cells generate ATP from both 
aerobic glycolysis in cytoplasm and mitochondrial OXPHOS. Galactose medium where 
galactose is the sole sugar source for mammalian cells will force them to rely on mitochondrial 
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OXPHOS, instead of glycolysis, to produce ATP 17. FCCP (carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone) the uncoupler of mitochondrial OXPHOS was used as a 
positive control 18.  After 24-hour treatment, FCCP, the uncoupler of mitochondrial OXPHOS 
showed a significant decrease in ATP production in galactose medium as compared to glucose 
medium, so did Mito-Chlor, while only marginal difference was observed with SQD1 treated 
groups (Figure IV-2E). This result suggests that the Mito-Chlor impaired ATP production by the 
mitochondrial OXPHOS while SQD1 did not. 
Furthermore, we performed immunoblot on three mitochondrial proteins to assess their 
protein expression (Figure IV-2F). Mito-Chlor displayed a dose-dependent decrease in protein 
levels of CYB, ATP6 and ND6 while SQD1 showed no reduction of these proteins. Therefore, 
although both SQD1 and Mito-Chlor inhibit the transcripts of mtDNA, Mito-Chlor finally 
decreases mitochondrial protein expression, impairs mitochondrial physiological function and 
inhibits mitochondrial OXPHOS; the effects of SQD1 is limited on mitochondrial transcription 
level. Therefore, Mito-Chlor has a more solid profile on regulating mitochondrial function, in 
terms of transcripts, proteins, and function. 
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Figure IV-2. The effects of SQD1 and Mito-Chlor on mitochondrial transcription, mitochondrial proteins and ATP 
production. (A) Transcription from the mitochondrial genome occurs on the L-strand (orange) and the H-Strand 
(blue) controlled by three promoters, HPS1, HSP2, and LSP. (B) Bru-seq trace diagrams of the mitochondrial 
transcripts after treatment with chlorambucil, Mito-Chlor and SQD1 in MIA PaCa-2 cells. Chlorambucil showed no 
effects on mitochondrial transcription, while Mito-Chlor blocked the transcription from the H-strand promoters. 
SQD1 treatment inhibited transcription from all three promoters. (C) SQD1 and Mito-Chlor reduce mitochondrial 
RNA levels of CYB, ATP6 and ND6 genes as represented by relative quantification (RQ) values determined from 
RT-PCR. Treatment conditions are the same as the Bru-seq experiments. * denotes p < 0.05, ** p < 0.005, and *** 
p < 0.0005. (D) TMRM measurement of mitochondrial membrane potential (MMP) in MIA PaCa-2 cells treated by 
SQD1 and Mito-Chlor at 4 h. CCCP (carbonyl cyanide 3-chlorophenylhydrazone) was used as a positive control. 
Treatment conditions are the same as the Bru-seq experiments. (E) ATP production measurement of SQD1, Mito-
Chlor and FCCP-treated MIA PaCa-2 cells in glucose and galactose medium. (F) Immunoblot of MT-CYB, MT-
ATP6 and MT-ND6 at 24 h treatment.  
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Mito-Chlor and SQD1 induce similar transcription profiles 
Besides targeting mitochondrial transcription effect, we further analyzed genome-wide 
transcriptomic profile of SQD1 and Mito-Chlor to understand its working mechanism in the cells.  
After comparing with DMSO control, SQD1- and Mito-Chlor-treated samples have in total 
12,336 common expressed genes with a strong Pearson correlation (r) of 0.52 (p < 2.2e–16) 
(Figure IV-3A). The common upregulated genes (log2FC > 1) have an r value of 0.45 (p < 2.2e–
16), and their common downregulated genes (log2FC < –1) have an r value of 0.34 (p < 2.2e–16) 
(Figure IV-3B, 3C). 19 of top 25 upregulated and 19 of top 25 downregulated protein-coding 
genes from SQD1 treatment were also altered in the Mito-Chlor-treated sample in the same 
direction. 
Examining the upregulated genes induced by SQD1 revealed some clues to its mechanism 
of action (Table VI-1). HMOX1, with the highest fold change (FC=315.4), encodes heme 
oxygenase 1 (HO-1), a protein that participates in the cellular defense against oxidative injury 19. 
Upregulated genes HK2, PFKFB4, DDIT4, ENO2 and HILPDA are related to HIF-1 (hypoxia-
inducible factor 1) signaling and the hypoxic response 20–22. SQD1 increased the transcription of 
a series of hypoxia-related genes. Genes related to biosynthesis and canonical glycolysis 
pathways were also induced, such as the expression of HK2, PFKFB4, ENO2, UPRT, and PGK1. 
The protein FOS (FC = 19.1) dimerizes with JUN (FC = 24.6) to form the transcription factor 
complex AP-1 23,24. Elevation of AP-1 regulates genes involved in cell growth, cell 
differentiation, and cell death 24,25. Besides FOS and JUN, the transcription of BHLHE40, 
C10orf10, and CSRNP1, involved in transcription activation, were also highly increased. 
Furthermore, SQD1 elevated the transcription of autophagy-related genes, such as BNIP3L, 
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MAP1LC3B, and GABARAPL1. Taken together, SQD1 induced a series of genes related to 
oxidative stress, transcription activation, metabolic pathways and cell death. 
Gene set enrichment analysis (GSEA) is a computational method that identifies classes of 
genes that are over-represented in a large set of genes 26,27. According to the GSEA results, 7 out 
of the top 20 upregulated gene sets and 10 out of the top 20 downregulated gene sets are in 
common between SQD1 and Mito-Chlor, indicating that they elicit similar responses in cells 
(Figure IV-3D, 3E). These gene sets are related to hypoxic response, redox signaling, MAPK 
signaling, cell proliferation, cell cycle and cell differentiation (Table IV-2). For the SQD1-
treated sample, hypoxia-related gene sets account for 11 out of the top 25 upregulated gene sets. 
The downregulated gene sets imply that SQD1 affects cell proliferation, cell cycle, and cell 
differentiation. Overall, SQD1 treatment induces cell signaling involved in hypoxic response, 
transactivation, glycolysis, and autophagy. 
 
Figure IV-3. SQD1 and Mito-Chlor share similar transcriptomic profiles and enriched gene sets. The comparisons 
between SQD1 and Mito-Chlor are displayed in heatmaps. (A) Total common genes. (B) Common upregulated 
genes. (C) Common downregulated genes. r is Pearson correlation. SQD1 and Mito-Chlor also share common 
upregulated (D) and downregulated (E) enriched gene sets with FDR < 0.001. Top 20 enriched gene sets ranked by 
FDR values were also compared between the two samples.  
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Table IV-1. Top 25 protein-coding genes upregulated by SQD1 in MIA PaCa-2 cells. FC, fold change. 
 
Gene 
name 
FC Gene 
name 
FC Gene 
name 
FC Gene 
name 
FC Gene 
name 
FC 
 HMOX1   315.4   ADM   40.0  BHLHE40   30.2  HSPA1A   28.3 GABARAPL1 24.1 
 ANKRD37   56.1   DDIT4   37.1  MAP1LC3B   29.6  CSRNP1   24.9 HSPH1 22.3 
 HK2   53.2  BNIP3L   34.7  ENO2   29.1  UPRT   24.6 PGK1 22.1 
 PFKFB4   40.9  CXCL8   31.7  C10orf10   28.8  JUN   24.6 TRIB3 21.3 
 SCAND2P   40.3  LUCAT1   31.0  HSPA1B   28.4  HILPDA   24.5 FAM162A 21.0 
 
Table IV-2. Common upregulated (A) and downregulated (B) enriched gene sets among the top 20 of SQD1 and 
Mito-Chlor. 
(A) 
                        
Common upregulated enriched gene sets  
PODAR_RESPONSE_TO_ADAPHOSTIN_UP 
CONCANNON_APOPTOSIS_BY_EPOXOMICIN_UP 
HELLER_SILENCED_BY_METHYLATION_DN 
GROSS_HYPOXIA_VIA_ELK3_DN 
NAGASHIMA_NRG1_SIGNALING_UP 
NAGASHIMA_EGF_SIGNALING_UP 
ZWANG_CLASS_3_TRANSIENTLY_INDUCED_BY_EGF 
 
(B) 
Common downregulated enriched gene sets  
KONG_E2F3_TARGETS 
LEE_EARLY_T_LYMPHOCYTE_UP 
GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_DN 
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_DN 
DUTERTRE_ESTRADIOL_RESPONSE_24HR_UP 
ROSTY_CERVICAL_CANCER_PROLIFERATION_CLUSTER 
CHANG_CYCLING_GENES 
GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_UP 
ZHANG_TLX_TARGETS_DN 
FUJII_YBX1_TARGETS_DN 
 
Evaluation of the cytotoxicity and ROS induction capability of SQD1 and Mito-Chlor 
We synthesized SQD1 and SQD2 to investigate the influence of styryl substitution. The 
4-styryl analog SQD1 (IC50 = 1.3 ± 0.18 μM) is more potent than 2-styryl analog SQD2 (IC50 = 
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3.9 ± 0.3 μM). Antiproliferative activity of SQD1 and Mito-Chlor was evaluated in MIA PaCa-2 
cells with and without antioxidants due to their potential effects on redox signaling. The 
combination with NAC significantly decreased the cytotoxicity of SQD1, implying that 
intracellular thiol-containing molecules may contribute to the detoxification of SQD1. The 
combination of vitamin E (Vit-E) slightly reduced the cytotoxicity of SQD1, again, suggesting 
that elevated oxidative stress within cells may contribute to their cytotoxicity (Table IV-3, 
Figure IV-4A). The rescue effect of NAC was also observed for Mito-Chlor, indicating that the 
cytotoxicity of Mito-Chlor is linked to ROS  (Table IV-3, Figure IV-4A). Additionally, SQD1 
displayed similar cytotoxicity across different cancer cells (Table IV-4).  
 
Table IV-3. Cytotoxicity of SQD1, SQD2 and Mito-Chlor in MIA PaCa-2 cells. aIC50 data are shown as mean ± 
standard deviation from three independent experiments. bNot tested.  
 
ID IC50 (μM)a +2 mM NAC +0.5 mM vit-E 
SQD1 1.3 ± 0.2 9.8 ± 3.8 2.1 ± 0.6 
SQD2 3.9 ± 0.3 NTb NT 
Mito-Chlor 42.0 ± 2.0 > 50 >50 
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Table IV-4. Cytotoxicity of SQD1 in a panel of cancer cell lines. IC50 (μM) values are shown as mean ± standard 
deviation from three independent experiments. 
 
 MDA-MB-231 
MDA-
MB-468 T-47D HUCCT1 TFK1 BxPC-3 PANC-1 
KYSE-
410 
KYSE-
70 
SQD1 3.2 ± 0.9 1.1 ± 0.2 1.2 ± 0.2 1.5 ± 0.6 5.6 ± 2.6 2.4 ± 0.2 1.1 ± 0.1 3.5 ± 0.1 2.9 ± 0.3 
 
Furthermore, we used CM-H2DCFDA dye, a general oxidative stress indicator, to 
measure ROS induced by SQD1 and Mito-Chlor 28,29. Relative fluorescence unit (RFU) 
represents the relative level of cellular ROS. SQD1 induced a moderate increase in the 
fluorescence while Mito-Chlor caused a significant increase in a time-dependent manner (Figure 
IV-4B). Moreover, the elevated fluorescence signal could be attenuated by NAC and Vit-E 
(Figure IV-4C), indicating that the ROS levels are increased upon compound treatments in MIA 
PaCa-2 cells. Dihydroethidium (DHE) was used as an independent redox probe for the detection 
of superoxide and hydrogen peroxide 30,31. The histogram shows a right shift of the DHE 
fluorescence in SQD1- and Mito-Chlor-treated samples as compared with the control, suggesting 
increased oxidative stress (Figure IV-4D). 
Given the mitochondrial transcription inhibition effect of SQD1 and Mito-Chlor, we next 
assessed mitochondrial superoxide level using the MitoSOX Red dye 32. Mitochondrial complex 
III inhibitor, antimycin A, a well-established stimulus of mitochondrial superoxide and ROS 
production was used as a positive control. SQD1, Mito-Chlor and antimycin A treatment 
increased fluorescence signal due to the induction of mitochondrial superoxid (Figure IV-4E). In 
contrast, chlorambucil and TPP treatment did not alter the mitochondrial superoxide level. 
In all, SQD1 and Mito-Chlor increased hydrogen peroxide, superoxide and other types of 
ROS in MIA PaCa-2 cells. 
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Figure IV-4. SQD1 and Mito-Chlor inhibit cell growth and increase ROS levels in MIA PaCa-2 cells. (A) NAC (2.0 
mM) or Vit-E (0.5 mM) protected cytotoxicity of SQD1 and Mito-Chlor. (B) Relative fluorescence unit (RFU) was 
measured at indicated time using CM-H2DCFDA dye. Tert-butyl hydroperoxide (TBHP) was used as a positive 
control. (C) The RFU of compound-treated MIA PaCa-2 cells in the presence or absence of Vit-E (0.5 mM) or NAC 
(3 mM) after 1-hour treatment. * denotes p < 0.05, ** p < 0.005. (D) Detection of superoxide and hydrogen 
peroxide in MIA PaCa-2 cells treated with SQD1 (5.4 μM), Mito-Chlor (51 μM), antimycin A (15 μM) or DMSO 
using DHE dye. (E) Detection of mitochondrial superoxide using MitoSOX Red superoxide indicator (2 μM) with 
fluorescence microscope. Objective: 20x. 
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SQD1 and Mito-Chlor induced similar protein expression patterns 
Immunoblot analysis of some proteins involved in the pathways from the GSEA analysis 
and encoded by the top upregulated protein-coding genes from SQD1 samples revealed that 
SQD1 treatment caused a robust increase in the expression of 6 proteins (Figure IV-5). These 
proteins are mostly involved in oxidative stress (HMOX1), transactivation (FOSB, C-JUN), 
metabolism regulation (HK2, PFKFB4), and induction of autophagy (MAPLC-3α/β, 
GABARAPL). The substantial upregulation of the components of transcription activator AP-1, 
JUN and FOS are likely to be responsible for the strong trend of transcription activation induced 
by the two compounds. As previously discussed, the most upregulated gene, HMOX1, its protein 
expression level increased during oxidative injury 19,33. SESN2 (encoding the protein sestrin 2) is 
another antioxidant induced under oxidative and genotoxic stress to protect cells against ROS 
was also significantly upregulated 34. The mitochondrial genome is especially vulnerable to 
oxidative damage since it does not contain protective histones 35. Oxidatively damaged 
mitochondria can be eliminated through autophagy to prevent excessive ROS production 36,37. 
The significant increase in GABARAPL and MAPLC-3α/β levels may indicate the induction of 
autophagy. SQD1 also upregulated protein expression of HK2 and PFKFB4, suggesting 
enhanced glycolysis (Figure IV-5). 
H2O2 triggers similar changes in protein levels of FOSB, c-JUN, HMOX1, HK2, PFKFB4, 
MAPLC-3α/β, and GABARAPL as compared to SQD1 (Figure IV-5). The antioxidant NAC 
attenuates the protein changes caused by SQD1 and H2O2, supporting the hypothesis that the 
induced cellular ROS had profound influences on the downstream signaling of SQD1 (Figure 
IV-5). Mito-Chlor also dose-dependently induced the expression levels of HMOX1, SESN2, 
FOSB, MAPLC3α/β, and c-JUN proteins, similar to SQD1 (Figure IV-5A, 5B). However, the 
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protein levels of glycolytic enzyme HK2, PFKFB4, and autophagy-related protein GABARAPL 
were not altered by Mito-Chlor (Figure IV-5A, 5B). The addition of NAC protected the 
upregulation of transcription activator AP-1 and HMOX1 induced by Mito-Chlor but had 
negligible influence on the expression levels of SESN2 and MAPLC3α/β (Figure IV-5).  
Figure IV-5. SQD1, Mito-Chlor, and H2O2 induce similar changes in protein expression in MIA PaCa-2 cells. (A) 
24 h treatment of SQD1 upregulated the expression levels of FOSB, c-JUN, HMOX1, HK2, PFKFB4, MAPLC-
3α/β and GABARAPL in a dose-dependent manner. Mito-Chlor treatment induced similar protein expression 
changes with the exception of GABARAPL, HK2, and PFKFB4. SQD1-, Mito-Chlor- and H2O2-induced changes in 
select protein levels were rescued by the addition of 1.5 mM NAC. (B) Protein levels induced by SQD1 and Mito-
Chlor were quantified by ImageJ and normalized to respective loading controls. The data are presented as mean ± 
standard deviation of at least three independent experiments. * denotes p < 0.05, ** p < 0.005, and *** p < 0.0005. 
(C) Transcription trace diagrams of the representative genes after SQD1 or Mito-Chlor treatment. The positive y-
axis represents plus-strand signal of transcription moving from left to right, and the negative y-axis represents 
minus-strand signal of transcription moving from right to left.  
 
In summary, SQD1 and Mito-Chlor are identified as mitochondrial transcription 
inhibitors (Figure IV-6). Their redox-modulating capability could partially contribute to the 
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mitochondrial transcription inhibition because H2O2 itself is able to cause mitochondrial 
transcription inhibition (Figure IV-2). However, their transcription inhibition pattern and the 
pathways to ROS induction are different. The mitochondrial superoxide increased by Mito-Chlor 
could be a downstream effect of its targeting and alkylating effects on mtDNA. SQD1, as a 
quinone redox recycler, it may also react with cysteines of some proteins, deplete GSH or 
alkylate DNA, resulting in cellular oxidative stress (Figure IV-6). Increasing studies have shown 
that mtDNA damage causes impairment of the respiratory complexes and a concomitant increase 
in mitochondrial ROS, leading to a vicious feed-forward cycle of additional mtDNA damage and 
ROS production 35. Furthermore, mtDNA damage could alter mitochondrial gene expression and 
interfere with mtDNA replication 35. Although SQD1, Mito-Chlor, and H2O2 all exhibit 
mitochondrial transcription inhibition, their transcriptional repression patterns and mitochondrial 
protein regulations are different. 
 
Figure IV-6. Proposed mechanisms of action of SQD1 and Mito-Chlor, and the adaptation pathways of pancreatic 
cancer cells in response to SQD1 and Mito-Chlor.  
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In this study, we demonstrate that Mito-Chlor represses transcription of the 
mitochondrial genome while its parent compound, chlorambucil, does not. A search of other 
small molecules that block transcription of mtDNA identified a novel quinone compound SQD1. 
Furthermore, the transcriptomic profile of Mito-Chlor was similar to that of SQD1 and both of 
these compounds induced mitochondrial superoxide and similar changes in protein expression in 
MIA PaCa-2 cells. SQD1, although deprived of a mitochondrial-directing group, shows promise 
in targeting mitochondria DNA via mitochondrial superoxide and other mechanisms. Taken 
together, as mitochondrial transcription inhibitors, SQD1 and Mito-Chlor are promising probes 
for the study of cell death related to mitochondrial function and oxidative stress. 
Materials and methods 
Cell culture and reagents. MIA PaCa-2, BxPC-3, PANC-1, KYSE-410, KYSE-70, and T-47D 
were cultured in RPMI 1640 medium supplemented with 10% FBS (v/v). MDA-MB-468 and 
MDA-MB-231 were cultured in L-15 medium supplemented with 10% FBS (v/v). HUCCT1 was 
cultured in RPMI 1640 medium supplemented with 1% penicillin/streptomycin (v/v) and 10% 
FBS (v/v). TFK1 cells was cultured in RPMI 1640 medium supplemented with 
penicillin/streptomycin (50 U/mL) and 10% FBS (v/v). Cells were maintained at 37 °C in a 
humidified atmosphere of 5% CO2. They were maintained in culture under 40 passages and 
tested regularly for mycoplasma contamination using Plasmo Test (InvivoGen). 
Chemicals. All commercial chemicals and solvents used for synthesis were reagent grade and 
were used without further purification unless otherwise specified. Chlorambucil was purchased 
from Oakwood Products, Inc., and Mito-Chlor was synthesized as described 12. 
Western blotting and antibodies. Cells were lysed in RIPA buffer (25 mM Tris-HCl, pH =7.4, 
150 mM NaCl, 1% Nonidet P-40, 0.5% Sodium deoxycholate, 0.1% SDS) supplemented with 
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Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific, 78443). Protein 
concentration was determined by BCA protein assay kit (Thermo Scientific, 23228, 23224). 
Unless otherwise described, 25-30 µg of protein was resolved by SDS–polyacrylamide gel 
electrophoresis (PAGE). Antibodies used for Western blots include C-Jun (Santa Cruz, SC-
74543), SESN-2 (Santa Cruz, SC-393195), HK2 (ThermoFisher, 700422), PFKFB4 
(ThermoFisher, PA5-15475), HMOX1 (Thermo Fisher, MA1-112), MAP LC3α/β (Santa Cruz, 
SC-398822), FOSB (Cell Signaling, 2251T), GAPDH (Cell Signaling, 2118S), GABARPAL1 
(Cell Signaling, 26632S), PARP (Cell Signaling, 9542S), Cleaved PARP (Cell Signaling, 5625), 
p-H2AX (Cell Signaling, 9718), MT-CYB (Abcam, ab81215), MT-ATP6  (Abcam, ab192423), 
MT-ND6 polyclonal antibody (Thermo Fisher, PA5-43532) and tubulin (Santa Cruz, SC-
101527). 
Colony formation assay. Cells were seeded in 24-well tissue culture plates at a density of 500 
cells per well or 96-well plates at 250 cells per well. After overnight attachment, cells were 
treated with compounds for 24 h. NAC or vitamin-E was added 1 h prior to the compound 
treatments. Then, the media containing compounds was removed and fresh media was added. 
After 7–10 days, when colonies had fully formed in the DMSO-treated wells, cells were stained 
with a 0.05% crystal violet solution for 30 min, and then washed with ddH2O to remove excess 
stain. Plates were imaged using Odyssey Imaging Systems (LI-COR Biosciences) after overnight 
drying. The colony density was quantified by Licor and ImageJ. 
CM-H2DCFDA ROS assay. MIA PaCa-2 cells were seeded in 96-well flat clear-bottom black 
tissue culture plates at a density of 1.5×104 per well. After overnight attachment, the media was 
removed and 100 µL CM-H2DCFDA dye (10 μM, Thermo Fisher, C6827) in HBSS was added 
to each well at 37 °C for 35–40 min. After removal of the dye solution, cells were washed with 
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pre-warmed DPBS for 2 times and then 80 µL HBSS was added. After pretreatment with or 
without NAC (3 mM), tested compounds were added in HBSS solution at designated 
concentrations. Fluorescent signal was then measured using CLARIO Star plate reader (Ex: 483 
± 15M; Em: 530 ± 20 nM). 
Bru-seq experiment and analysis. MIA PaCa-2 cells were seeded in 10 cm dishes in duplicates. 
Twenty-four hours later, cells were treated with DMSO, SQD1 (5.4 μM), Mito-Chlor (51 μM), 
Chlor (233 μM) or H2O2 (50 μM, 150 μM and 300 μM) for 4 h. Bromouridine (Bru) was added 
to the media during the last 30 min of treatment to a final concentration of 2 mM as previously 
described 13. Cells were then collected in TRIZOL and total RNA was isolated. The Bru-labeled 
nascent RNA was immunocaptured using anti-BrdU antibodies conjugated to magnetic beads. 
The cDNA libraries (Illumina TrueSeq) converted from the bromouridine-labeled RNA were 
sent for deep sequencing to the University of Michigan Sequencing Core. Sequencing reads (~40 
million per sample) were mapped to the hg38 reference genome. Enriched gene sets were 
analyzed using GSEA. Hierarchical clustering was performed using log2FC of gene expression. 
R programming language (Version 3.5.1) was utilized to produce select figures. 
MitoSOX imaging. MIA PaCa-2 cells were seeded in 96-well clear-bottom black tissue culture 
plates at a density of 5000 cells per well. After overnight attachment, media was removed and 
100 μL HBSS solution was added into each well. The cells were treated with SQD1 (5.4 μM), 
Mito-Chlor (51 μM), chlorambucil (233 μM), TPP (51 μM), antimycin A (15 μM) or DMSO, 
respectively. After 1-hour incubation at 37˚C, the medium was removed. HBSS working 
solution with 5 μM MitoSOX dye (Thermo Fisher, M36008) and 4 μg mL–1 Hoechst 33342 
(Thermo Fisher, H3570) were added and incubated for 15 minutes. Cells were then washed 
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gently three times with warm HBSS buffer before imaging by the OLYMPUS DP80 system with 
RFP and DAPI filters using the 20 X objective. 
DHE staining analyzed by flow cytometry. MIA PaCa-2 cells were seeded in 6-well plates at a 
density of 400,000 cells per well. After overnight attachment, medium was removed, and the 
cells were washed with HBSS solution once. A solution of 5 μM DHE dye in HBSS pre-warmed 
buffer was added to each well. After incubation at 37 °C for 30 min, tested compounds were 
added. Plates were covered and incubated for an additional hour at 37 °C and protected from 
light. Staining buffer was carefully aspirated, and 0.5 mL trypsin was added to detach the cells. 
Complete medium (0.5 mL) was added to each well to neutralize the trypsin and then cells were 
transferred to centrifugal tubes to pellet the cells. Supernatant was discarded and cells were 
resuspended in HBSS buffer. The fluorescence of DHE was measured using a flow cytometer 
(ZE5 cell analyzer, Bio-Rad) with excitation at 488 nm and emission at 530 nm. At least 10,000 
events were collected. Histograms were analyzed by Flowjo (Version 8). 
RNA preparation and real-time PCR (RT-PCR). MIA PaCa-2 cells were seeded into 6-well 
tissue culture plates at a density of 3×105 per well and allowed to attach overnight before treating 
with drugs at specified time. RNAs were collected using Direct-zol RNA Miniprep kit (Zymo 
Research). RNA (1 μg) from each sample was reverse-transcribed into cDNA using the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). RT-PCR was performed using 
Viia 7 Real-Time PCR System (Thermo Scientific) with TaqMan Gene Expression Master Mix 
(Thermo Scientific). RT-PCR primers (MT-ND6, MT-ATP6, MT-CYB, HMOX1, GAPDH) 
were purchased from Thermo Scientific. Relative expression levels were normalized to GAPDH 
and fold changes in mRNA expression level were evaluated using the 2–ΔΔCt method. 
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Mitochondrial membrane potential detection. MIA PaCa-2 cells were seeded into 6-well 
tissue culture plates at a density of 3×105 per well and allowed to attach overnight before treating 
with compounds at specified time. Cells were then resuspended and incubated with 20 nM 
TMRM (Thermo Fisher, M20036) in HBSS solution at 37 °C for 30 min and protected from 
light. CCCP (50 μM) was used as a positive control. After removing the dye, the fluorescence 
intensity was measured by Bio-Rad ZE5 Analyzer flow cytometer (Ex: 561 nm; Em: 590 nm). 
The percentage of TMRM fluorescence level of the treatment groups compared to the control 
group represents the relative mitochondrial membrane potential. 
Quantification of total cellular ATP in glucose and galactose medium. RPMI 1640 medium 
(Thermo Fisher, 11875101) was used as glucose medium. Galactose medium was prepared by 
adding 10 mM galactose (Sigma-Aldrich, G0750) to RPMI 1640 medium with no glucose 
(Thermo Fisher, 11879020). Cells were seeded into 96-well plates (Corning, 3603) at a density 
of 10,000 cells/well. The total cellular ATP content was determined 24 hours after compound 
treatment using the CellTiter-Glo® Luminescence Cell Viability Assay according to the 
manufacturer’s protocol (Promega Corporation, G7570). Luminescence signals were quantified 
using a scanning microplate reader (BMG Labtech). 
Immunoblot. MIA PaCa-2 cells were seeded into 6-well tissue culture plates for 2.5×105 cells 
per well and allowed to attach overnight before treating with appropriate compounds at indicated 
concentrations. Then, cells were lysed with RIPA buffer in the presence of protease and 
phosphatase inhibitors. The cells were collected, centrifuged and the pellet was discarded. 
Protein concentration of whole cell lysate in the supernatant was determined by BCA protein 
assay kit. Proteins were resolved on 8-15% SDS-PAGE and electrotransferred to transfer 
membrane (Immobilon®-FL). After incubating in blocking buffer (5% nonfat dry milk in TBST) 
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at room temperature for 1 h, membranes were probed with primary antibody (1:500–1:1000) in 
blocking buffer overnight at 4 °C. Next day, membranes were washed 3 times for 5 min with 
TBST, followed by incubation in anti-rabbit or anti-mouse secondary antibody (Dylight 800 4× 
PEG conjugated; Thermo Scientific; 1:5000) in blocking buffer at room temperature for 1 h. The 
membranes were washed 3 times with TBST and imaged by Odyssey® CLx Imaging System. 
Protein levels were quantified by ImageJ 1.52a and the relative density of each band was 
normalized by respective loading controls. 
Statistical analysis. Statistical analysis was conducted using GraphPad Prism (Version 6.0), R 
programming (Version 3.5.1). All data are shown as mean ± standard deviation from at least 3 
independent experiments. Significance levels for assays and immunoblots were determined 
using the unpaired Student's t-test between two groups using Microsoft Excel. Significance 
levels for transcriptomic profile comparisons were calculated using R. 
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CHAPTER V 
Mechanistic Studies of Quinolin-Chlorobenzothioate Derivatives with Proteasome 
Inhibitory Activity 
The human 26S proteasome is an essential protein degradation machinery designated to 
maintain cellular homeostasis via removal of unfolded and misfolded proteins, and it is involved 
in balancing cell survival and apoptotic cell death. Importantly, small molecule proteasome 
inhibitors activate unfolded protein response leading to cancer cell death and are attractive for 
cancer therapy 1,2. Bortezomib, ixazomib and carfilzomib were approved for treating multiple 
myeloma or mantle-cell lymphoma as proteasome inhibitors. They have boronic acid or 
epoxyketone scaffold, known to interact with the N-terminal threonine residues in the catalytic 
subunits of the proteasome thus blocking its activity (Figure V-1) 1. Derivatives of the approved 
proteasome inhibitors have shown efficacy in multiple cancers and are currently undergoing 
clinical trials in solid tumors, including pancreatic cancer 1-4. Unfortunately, patients frequently 
develop resistance to these therapies due to either point mutations on the drug binding site or 
induction of alternative compensatory mechanisms such as the aggresome pathway 5. Therefore, 
development of proteasome inhibitors with different scaffolds and mechanisms of action would 
be critical to overcome tumor cell resistance to first-line proteasome inhibitors. 
Pancreatic cancer is a difficult cancer to treat due to its rapid metastatic spread and late-
stage diagnosis 6. Pancreatic ductal adenocarcinoma (PDAC) is the major type of pancreatic 
Notes: This work has been published as Hu, S., Jin, Y., Liu, Y., Ljungman, M. & Neamati, N. Eur. J. Med. 
Chem. 158, 884–895 (2018). 
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cancer and is predicted to become the second most common cause of cancer-related death within 
the next decade in the United States 7,8. Pancreatic tumor cells can rapidly develop resistance to 
current chemotherapies, such as gemcitabine, nab-paclitaxel and FOLFIRINOX 9,10. Thus, it is 
essential to develop more effective therapeutics to better treat this dreadful disease. Inhibition of 
the ubiquitin-proteasome pathway contributes to apoptotic cell death in pancreatic cancer 11,12. 
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum (ER) stress and 
apoptosis13. Additionally, proteasome activator subunit 3 (PSME3) promotes pancreatic cancer 
growth by activating the proteasome activity 14. Therefore, the proteasome is an attractive target 
for therapeutics in pancreatic cancer. 
In a medium-throughput phenotypic screen of 20,000 diverse drug-like compounds, we 
identified a quinolin-chlorobenzothioate, QCBT7, with submicromolar cytotoxicity in the colon 
carcinoma cell line HCT 116. It was previously shown that the structurally similar compound 8-
quinolinethiol hydrochloride (8TQ) inhibits the essential proteasome deubiquitinase Rpn11, 
instead of the catalytic subunit of the proteasome, suggesting that QCBT7 may also affect 
proteasome function (Figure V-1) 15. Quinoline derivatives possess antibacterial, antimalarial 
and anticancer activities. Thioester, amide and ester derivatives of quinoline have been used in 
antimicrobial and anticancer research 16-19. To further identify new quinoline derivatives with 
potential proteasome inhibition and anticancer activities, we synthesized 21 analogs of QCBT7 
to establish structural requirements for potency. We then profiled nascent RNA and protein 
expression in QCBT7-treated pancreatic cancer cells to understand how these cells respond to 
the treatment. Our results demonstrate that the induced transcription and protein patterns 
following QCBT7 treatment resemble those obtained for MG132 and ixazomib, indicating that 
QCBT7 blocks proteasome activity and induces hypoxic response, ER stress and glycolysis.   
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Figure V-1. Structures of select proteasome inhibitors and the lead compound QCBT7. Carfilzomib and epoxomicin 
are epoxyketone-based compounds, and bortezomib and ixazomib are boronate-containing compounds. MG132 is a 
peptide aldehyde. 8TQ is 8-quinolinethiol hydrochloride. QCBT7 has a similar scaffold to 8TQ. 
 
Results and discussion 
In a medium-throughput screen of 20,000 drug-like compounds derived from a diverse 
library, QCBT7 was one of the most cytotoxic hits and had an IC50 value of 0.6 µM in HCT 116 
cells 20. QCBT7 was further tested in the pancreatic cancer cell lines, showing IC50 values of 2.6 
µM and 1.1 µM in MIA PaCa-2 and PANC-1 cells, respectively (Table V-1). Considering the 
stability of the thioesters in the cellular reducing environment, we synthesized ester and amide 
derivatives of QCBT7 to potentially increase the stability and maintain cytotoxicity. 
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Table V-1. Cytotoxicity of 8-thioester/ester/amide-quinoline derivatives of QCBT7 in a panel of cancer cell lines. 
Data are shown as mean ± standard deviation from at least three independent experiments. 
  
Compound 
IC50 (µM) 
MIA PaCa-2 PANC-1 HCT 116 KYSE-70 
3a 3.3 ± 0.2 1.5 ± 0.4 1.1 ± 0.4 1.1 ± 0.3 
3b 3.4 ± 0.3 1.5 ± 0.6 1.1 ± 0.6 1.3 ± 0.1 
3c (QCBT7) 2.6 ± 0.6 1.1 ± 0.1 0.6 ± 0.3 0.8 ± 0.1 
3d 2.4 ± 0.8 0.9 ± 0.3 0.5 ± 0.3 0.7 ± 0.1 
3e >20 >20 >20 >20 
3f 4.9 ± 3.3 1.7 ± 0.1 1.5 ± 0.6 0.9 ± 0.2 
3g 3.6 ± 0.1 0.9 ± 0.4 0.7 ± 0.1 0.6 ± 0.1 
3h 10.3 ± 5.6 9.4 ± 4.4 4.7 ± 1.5 11.8 ± 0.5 
3i 6.5 ± 0.7 5.1 ± 2.1 4.0 ± 0.7 6.9 ± 0.1 
3j 6.5 ± 0.1 7.1 ± 1.1 3.0 ± 0.8 15.2 ± 5.7 
3k 5.4 ± 0.4 4.9 ± 1.4 3.7 ± 1.1 6.6 ± 0.2 
3l >20 >20 >20 >20 
3m 7.0 ± 0.4 7.6 ± 1.2 4.2 ± 2.0 4.1 ± 0.3 
3n 5.8 ± 0.8 5.5 ± 0.2 2.9 ± 0.1 6.5 ± 0.3 
3o >20 >20 >20 >20 
3p >20 >20 >20 >20 
3q >20 >20 >20 >20 
3r >20 >20 >20 >20 
3s >20 >20 >20 >20 
3t >20 >20 >20 >20 
3u >20 >20 >20 >20 
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Synthesis of QCBT7 and its derivatives 
Derivatives of QCBT7 were prepared according to the general procedure shown in 
Scheme IV-1 by Dr. Yi Jin. Benzoyl chloride or benzyl chloride was reacted with 8TQ, 8-
hydroxylquinoline or 8-aminoquinoline, respectively, in the presence of potassium carbonate in 
dimethylformamide (DMF) to afford final products 3a-3u in 72-95% yields.  
Scheme V-1. Preparation of QCBT7 derivatives. 
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8-thioester and 8-ester quinoline derivatives are more cytotoxic than 8-amide quinoline 
derivatives 
Cytotoxicity of QCBT7 and its derivatives was assessed using the colorimetric MTT 
assay in a panel of cancer cell lines (Table V-1). The 8-thioester derivatives (3a-d, 3f, 3g) had 
similar IC50 values around 1 - 4 μM，while the 8-ester derivatives (3h-k, 3m, 3n) were less 
potent (IC50: 5-10 μM). Different substituents on the benzene ring (R group in Scheme V-1) had 
little effect on the cytotoxicity of the compounds. The 8-amide derivatives (3o-r, 3t, 3u) were 
much less cytotoxic (IC50 > 20 μM) although the amide-quinoline was more stable than the 
ester-quinoline and thioester-quinoline in the cellular reducing environment. The ether analogs 
3e and 3l were inactive. These results suggest that the thioester-quinoline and ester-quinoline 
scaffolds are responsible for the cytotoxicity of this series of compounds. Due to the substantial 
reduction in cytotoxicity of the amide-quinoline derivatives and similar high potency among 8-
thioeter-quinoline analogs, we selected QCBT7 for further stability and mechanistic studies.  
QCBT7 is more stable than 8TQ in solution 
To assess the chemical stability of QCBT7, we performed liquid chromatography mass 
spectrometry (LCMS) of QCBT7 at three different time points after it was added to DMSO or to 
a 1:1 DMSO/water solution. N-acetylcysteine (NAC) was added in the solution to simulate a 
reducing environment and react with free thiols in the solution. 8TQ is the parent compound 
from which QCBT7 was synthesized, and is likely to be the functional scaffold for this series of 
compounds. QCBT7 was more stable than 8TQ under a range of conditions (Table V-2). In 100% 
DMSO, QCBT7 was still intact after seven days, while 8TQ formed dimers once it was 
dissolved in DMSO. Addition of NAC did not affect the results, and 8TQ also reacted with NAC 
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forming a conjugate at two and five hours. In a 1:1 solution of DMSO and water, 8TQ formed 
dimers within one minute, while QCBT7 was stable and present in a monomeric form after 48 
hours. Additionally, NAC reacted with 8TQ as early as one minute, but did not react with 
QCBT7 in the 1:1 solution. In conclusion, QCBT7 is more stable than 8TQ in DMSO and 1:1 
solution of DMSO and water, and NAC has little effect on QCBT7 even after 48-hour incubation. 
Therefore, we selected QCBT7, the more stable compound, for mechanistic studies 
Table V-2. Stability of (a) QCBT7 and (b) 8TQ in DMSO and 1:1 DMSO/water solution with or without NAC. N/A: 
not measured at the time point.  
(a) Percent of QCBT7 remaining 
Time / h DMSO DMSO+NAC 1:1 DMSO/water 1:1 DMSO/water+NAC 
2 N/A 100 100 100 
24 N/A 100 100 100 
48 100 (> 7 days) 97.8 97.6 100 
(b) Percent of 8TQ remaining 
Time / h DMSO DMSO+NAC 1:1 DMSO/water 1:1 DMSO/water+NAC 
0.017 74.9 72.8 78.7 72.2 
0.5 34.6 N/A N/A N/A 
2 0 13.1 13.3 7.6 
5 N/A 0 0 0 
 
QCBT7 upregulates gene sets related to proteasome inhibition, unfolded protein response, 
glycolysis, and hypoxia 
To better elucidate the potential mechanisms of action of QCBT7 in pancreatic cancer, 
we utilized Bru-seq technique to assess its effects on nascent transcription signatures in MIA 
PaCa-2 cells. After cells treated with 3.3 µM QCBT7 for 4 h, we observed 326 upregulated 
genes with fold change (FC) over 2 and 127 downregulated genes with FC below 0.5 (Table V-
3). In the set of upregulated genes, STRING analysis revealed three major biological processes: 
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carbon metabolism, HIF-1 signaling pathway and glycolysis 21. We performed gene set 
enrichment analysis (GSEA) using all the genes ranked by the log2-fold change from the Bru-
seq results 22,23. The CONCANNON_APOPTOSIS_BY_EPOXOMICIN_UP gene set was 
ranked as the 13th enriched gene set of the C2 curated gene sets from the Molecular Signatures 
Database (MSigDB), suggesting that QCBT7 causes a similar transcriptional response to 
proteasome inhibitor epoxomicin (Figure V-2A). Epoxomicin is a potent, selective, irreversible 
and cell-permeable 20S proteasome inhibitor (Figure V-1) 24. Additionally, we observed the 
enrichment of genes involved in the unfolded protein response (UPR), glycolysis and hypoxia in 
the Hallmark gene sets (Figure V-2B, 2C, 2D). Notably, a much higher number of hypoxia-
related genes were upregulated (158) than downregulated (13) by QCBT7 (Figure V-2E). Other 
gene sets indicated that QCBT7 also stimulated the transcription of genes involved in apoptotic 
cell death. Taken together, the results from STRING and GSEA are consistent, and we 
hypothesize that QCBT7 causes proteasome inhibition, hypoxic response, glycolysis and 
unfolded protein response.  
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Figure V-2. QCBT7 upregulated the gene sets related to proteasome inhibition, unfolded protein response (UPR), 
glycolysis and hypoxic response. (A-D) GSEA enrichment plots for top enriched gene sets matched with 
upregulated genes from QCBT7 Bru-seq sample (FDR <= 0.001). (A) Epoxomicin, a proteasome inhibitor. (B) UPR. 
(C) Glycolysis. (D) Hypoxia. Size is the number of genes, and NES is the normalized enrichment score for each 
gene set.  (E) Log2FoldChange of 1387 hypoxia-related genes from QCBT7 Bru-seq results. 1 and -1 are used as 
the cutoff values for upregulated and downregulated genes. 
 
Table V-3. Top 50 upregulated genes in QCBT7-treated MIA PaCa-2 cells. FC is fold change, defined as treatment 
over control. HMOX1, PFKFB4, PDK1, PGK1, EGLN1, ENO2 and HK2 are involved in the HIF-1 signaling 
pathway. PGK1, ENO2, HK2 and PGD are related to carbon metabolism. PGK1, ENO2 and HK2 affect glycolysis. 
         
Gene FC Gene FC Gene FC Gene FC Gene FC 
 HMOX1   149  BNIP3L   15 BTG1 9 ENO2 8 ZNF395 6 
 LOC344887   45   ADM   14 PGK1 9 GLA 7 GBE1 6 
 OSGIN1   36  GCLC   13 IL8 9 TXNRD1 7 PAM 6 
 PFKFB4   32  PDK3   12 ANGPTL4 8 EID3 7 HK2 6 
 MIR210HG   30  TNFSF9   12 NQO1 8 SRXN1 7 PGD 6 
 SLC7A11   27  FAM162A   12 EGLN1 8 P4HA1 6 INSIG2 5 
 DOK3   24  PDK1   11 DDIT4 8 JUNB 6 DUSP5 5 
 SCAND2   23  ARRDC3   10 DNAJB4 8 PIR 6 CCNG2 5 
 ANKRD37   21  RNF122   9 HILPDA 8 UPRT 6 RNF24 5 
 P4HA2   19  CHAC1   9 C3orf58 8 WSB1 6 ERO1L 5 
 
QCBT7 has similar expression signatures to proteasome inhibitors and hypoxia inducers 
To further test our hypothesis that QCBT7 inhibits proteasome activity and induces 
hypoxia, glycolysis and ER stress, we performed connectivity map (CMAP) analysis of QCBT7 
Bru-seq results (Table V-4) 25. In the top 50 correlated perturbagens (small molecules and 
genetic reagents causing gene expression changes in cell lines), knockdown of PSMD1, PSMB5 
and PSMA1 are listed, which encode different proteasome subunits. Additionally, proteasome 
inhibitors, such as MG132 and MLN-2238 (ixazomib), display similar expression signatures to 
QCBT7. Hypoxia-inducible factor (HIF) activators, such as VU-0418947-2 and VU-0418946-1, 
also show high similarity (high connectivity score), suggesting that QCBT7 induces hypoxic 
 
 
 
 
 
 
 112 
response. Taken together, CMAP analysis supports the hypothesis that QCBT7 causes 
proteasome inhibition and elicits a hypoxic response.  
Table V-4. Connectivity map analysis of QCBT7. Top compound perturbagens (CP), gene over-expression 
perturbagens (OE), gene knock-down perturbagens (KO) and perturbational class member (PCL) are listed. 
Pc_selection is the connectivity score (from -100 to 100). A positive higher score means more positive connection 
between the perturbagen and QCBT7. 
 
Type Name Description Pc_selection 
CP VU-0418947-2 hypoxia inducible factor activator 99.89 
CP VU-0418946-1 hypoxia inducible factor activator 99.86 
CP MG-132 proteasome inhibitor 99.58 
CP MLN-2238 proteasome inhibitor 99.3 
OE NFE2L2 basic leucine zipper proteins, nuclear factor 
(erythroid-derived 2)-like 2 
99.91 
KD PSMD1 Proteasome subunits, proteasome (prosome, 
macropain) 26S subunit, non-ATPase, 1 
99.82 
KD PSMB5 Proteasome subunits, proteasome (prosome, 
macropain) subunit, beta type, 5 
99.61 
KD PSMA1 Proteasome subunits, proteasome (prosome, 
macropain) subunit, alpha type, 1 
99.45 
PCL HIF activator N/A 100 
PCL Proteasome inhibitor N/A 99.72 
 
QCBT7 and MG132 have similar transcriptional profiles 
MG132, a peptide-aldehyde proteasome inhibitor, blocks the proteolytic activity of the 
26S proteasome by covalently binding to the 20S catalytic subunit 26. Due to its lack of 
specificity, it has only been used as a research tool to study the ubiquitin-proteasome pathway. 
In a separate study, we performed Bru-seq of MG132-treated HeLa cancer cells. Although a 
different cell line, we still identified similarity in the 
CONCANNON_APOPTOSIS_BY_EPOXOMICIN_UP gene set and 
WINTER_HYPOXIA_METAGENE gene set between QCBT7 and MG132. 
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QCBT7 and MG132 share 53 common upregulated enriched gene sets (FDR < 0.001) 
from C2 curated gene sets (Figure V-3A). Treatments with QCBT7 and MG132 induced 51 
common genes contributing to the enrichment of the 
CONCANNON_APOPTOSIS_BY_EPOXOMICIN_UP gene set (Figure V-3B, 3C). Moreover, 
their transcript expressions were strongly correlated (r = 0.69, p = 2.07e-08) (Figure V-3D). 
STRING analysis indicates that the 51 common upregulated genes are involved in apoptotic 
signaling pathway, unfolded protein response and ER stress. Furthermore, we observed 22 
common genes in the WINTER_HYPOXIA_METAGENE gene set from both QCBT7- and 
MG132-treated samples, and their nascent transcript expressions also had a strong correlation (r 
= 0.68, p = 5.64e-04) (Figure V-3E, 3F, 3G). These 22 genes are related to the HIF-1 signaling 
pathway, glycolysis and cellular stress. 
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Figure V-3. QCBT7 and MG132 have common enriched gene sets in proteasome inhibition pathway and hypoxic 
response. (A) Venn diagram of all upregulated enriched gene sets between QCBT7 and MG132 (FDR < 0.001). (B) 
GSEA enrichment plots of CONCANNON_APOPTOSIS_BY_EPOXOMICIN_UP gene set in QCBT7 and MG132 
Bru-seq samples. (C) 51 genes in common from the EPOXOMICIN gene set. (D) Heatmap of the 51 common genes 
using log2FC (r = 0.69, p = 2.07e-08). (E) GSEA enrichment plots of WINTER_HYPOXIA_METAGENE gene set 
in two samples. (F) 22 genes in common from the HYPOXIA gene set. (G) Heatmap of the 22 common genes using 
log2FC (r = 0.68, p = 5.64e-04). 
 
Together, these results demonstrate that QCBT7 is similar to the proteasome inhibitor 
MG132 at the transcription level and regulates redox signaling and ER stress. GCLM, HMOX1, 
NQO1 and SQSTM1, from the 51 common genes in the EPOXOMICIN gene set, are involved 
in redox signaling pathways. GCLM encodes a glutamate-cysteine ligase modifier subunit, 
which is a rate-limiting enzyme for glutathione synthesis. HMOX1 (heme oxygenase 1) 
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responds to cellular oxidative stress and catalyzes cleavage of heme in order to maintain redox 
balance 27. NQO1 (NAD(P)H quinone dehydrogenase 1) can also prevent oxidative stress via 
reducing quinones to hydroquinones. In addition, SQSTM1 (sequestosome 1) mediates the 
activation of NF-κB signaling together with TNF receptor-associated factor 6, and is a positive 
regulator of Nrf2 signaling 28. CEBPB, DDIT3 and PPP1R15A are three ER stress-related genes 
induced by both QCBT7 and MG132. Proteasome inhibitors may stimulate CEBPB, a 
transcription factor that interacts with DDIT3/CHOP, an ER stress biomarker, to induce cellular 
stress and cause cancer cell death 27,29. PPP1R15A (GADD34) sensitizes cells to proteasome 
inhibitors by promoting ER stress, reactive oxygen species production and autophagy 30.  
Proteasome inhibitors can regulate redox homeostasis and induce ER stress 1,27. MG132 
has been shown to activate the Nrf2-ARE signaling pathway that protects cells from oxidative 
stress 31. The inhibition of proteasome activity caused by MG132 leads to the unfolded protein 
response and apoptosis 26,32. The findings in our study are consistent with previous reports on the 
mechanisms of action of MG132. Moreover, they are similar to those of QCBT7 implied from 
the STRING and GSEA results. 
QCBT7 induces the accumulation of ubiquitylated proteins 
To investigate whether QCBT7 inhibits proteasome activity as suggested from Bru-seq 
analysis, immunoblot was performed using the antibody against the ubiquityl group of 
ubiquitylated proteins in QCBT7-treated pancreatic cancer cells. Ubiquitylated proteins are 
normally subjected to proteasome-mediated degradation, but inhibition of the proteasome results 
in the accumulation of slower-migrating ubiquitylated proteins. QCBT7 treatment resulted in the 
dose-dependent accumulation of ubiquitylated proteins in both MIA PaCa-2 and PANC-1 cells 
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(Figure V-4). Similarly, both MG132 and ixazomib caused a significant accumulation of 
ubiquitylated proteins (p < 0.005). QCBT7 showed a stronger accumulating effect than MG132 
in PANC-1, while ixazomib was the most potent inducer of ubiquitylated proteins in both cell 
lines. These results support the hypothesis that QCBT7 has proteasome inhibitory activity. 
Ixazomib, which reversibly and selectively bind to the proteasome beta 5 subunit (PSMB5) of 
the 20S catalytic subunit, has been approved as an orally bioavailable proteasome inhibitor for 
the treatment of multiple myeloma and is currently being tested in combination with other 
standard-of-care treatments in clinical trials for solid tumors 33,34. 
We also tested 2-chlorobenzoic acid (2-CBA), a potential by-product of QCBT7 in the 
cellular reducing environment (Figure V-4). 2-CBA did not cause accumulation of ubiquitylated 
proteins, suggesting that QCBT7 or 8TQ is the active proteasome inhibitory molecules.  
            
Figure V-4. QCBT7 causes the accumulation of ubiquitylated proteins in MIA PaCa-2 and PANC-1 cell lines, 
similar to MG132 and ixazomib. Cells were treated with QCBT7, MG132, ixazomib and 2-chlorobenzoic acid (2-
CBA) for 24 h. MG132 and ixazomib were used as positive controls. FC: fold change, relative expression of the 
protein normalized to GAPDH expression. Data shown are representative of three independent experiments. Error 
bars represent standard deviation. * denotes p < 0.05, ** denotes p < 0.005 and *** denotes p < 0.0005 compared 
with DMSO control 
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QCBT7 increases the protein expression of genes related to glycolysis, ER stress and 
hypoxia in pancreatic cancer cells 
To validate proteins and signaling pathways identified with the Bru-seq analysis, we 
performed immunoblot of selected genes related to glycolysis, ER stress and hypoxia in MIA 
PaCa-2 and PANC-1 cells. HK2 (hexokinase 2) and PFKFB4 (6-phosphofructo-2-
kinase/fructose-2, 6-biphosphatase 4) are two glycolytic genes among the top 50 upregulated 
genes (Figure V-5A, Table V-3). QCBT7 elevated HK2 and PFKFB4 protein expression dose-
dependently in both MIA PaCa-2 and PANC-1 cells (Figure V-5B), and it significantly increased 
their protein expression at 3.3 μM (Figure V-5C, p < 0.05). HK2 and PFKFB4 are related to 
hexose metabolic processes and their protein expression increases under hypoxic conditions 35.  
QCBT7 also induced CHOP expression, which is a protein biomarker for ER stress 
(Figure V-5B). Moreover, MG132 and ixazomib significantly increased PFKFB4 and CHOP 
expression, but not HK2, suggesting that they also have some differences in the downstream 
signaling due to potential distinct binding sites of the proteasome.  
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Figure V-5. QCBT7 increases nascent RNA and protein expression of genes related to glycolysis and ER stress in 
pancreatic cancer cells. (A) Trace diagrams of nascent RNA expression of HK2 and PFKFB4. Blue represents 
QCBT7 treatment and yellow represents the DMSO control. (B) Immunoblot of HK2, PFKFB4 and CHOP in MIA 
PaCa-2 and PANC-1 cells after 24 h treatment. FC: fold change, relative expression of the protein normalized to 
GAPDH expression. Data shown are representative of 3 independent experiments. (C) Quantification of relative 
expression of each protein in 3 independent experiments. Data are reported as mean ± standard deviation. * denotes 
p < 0.05 compared with DMSO control.  
 
Furthermore, QCBT7 increased the expression of hypoxia-related proteins, including 
HIF1A, SESN2, TRXR1, NQO1, HMOX1 and SLC7A11 (Figure V-6). At the nascent transcript 
level, NQO1, HMOX1 and SLC7A11 were dramatically upregulated by QCBT7 (Figure V-6A). 
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HMOX1 and SLC7A11 protein expression also increased significantly by 6.6 μM QCBT7, and 
NQO1 showed dramatic increase in protein expression in PANC-1 but not MIA PaCa-2 cells 
(Figure V-6B, 6C). HIF1A, SESN2 and TRXR1 were upregulated by QCBT7 in both cell lines, 
and HIF1A and SESN2 showed a dose-dependent increase (Figure V-6B). MG132 and ixazomib 
had similar effects on HIF1A, SESN2, HMOX1 and SLC7A11 protein levels (Figure V-6B, 6C). 
SESN2 (sestrin 2) is inducible by hypoxia and oxidative stress conditions to balance metabolic 
homeostasis 36. HMOX1 is a downstream target of HIF1A, and is sensitive to cellular redox 
signaling 37. In addition, hypoxia affects glutathione metabolism 35. TRXR1 (thioredoxin 
reductase 1) was elevated by QCBT7 to possibly balance the increase of HIF1A and maintain 
redox homeostasis. SLC7A11 (solute carrier family 7 member 11), which regulates glutamate 
transport, also showed an increased expression with the treatment 38.  
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Figure V-6. QCBT7 increases nascent RNA and protein expression of genes related to hypoxia in pancreatic cancer 
cells. (A) Trace diagrams of nascent RNA expression of NQO1, HMOX1 and SLC7A11. Blue represents QCBT7 
treatment and yellow represents the DMSO control. (B) Immunoblot of HIF1A, SESN2, TRXR1, NQO1, HMOX1 
and SLC7A11 in MIA PaCa-2 and PANC-1 cells after 24 h treatment. FC: fold change, relative expression of the 
protein normalized to GAPDH expression. Data shown are representative of 3 independent experiments. (C) 
Quantification of relative expression of each protein in 3 independent experiments. Data are reported as mean ± 
standard deviation. * denotes p < 0.05, ** denotes p < 0.005 and *** denotes p < 0.0005 compared with DMSO 
control.  
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Our immunoblot results of MG132 and ixazomib corroborate the previously reported 
mechanisms of proteasome inhibitors in inducing hypoxia and ER stress. MG132 increases the 
protein level of SESN2 due to the accumulation of ubiquitylated SESN2, and it is dependent on 
Nrf2 36. MG132, ixazomib and bortezomib increase HMOX1 and CHOP expression level due to 
Nrf2 signaling and ER stress 27,31-34,39. Compared with MG132 and ixazomib, QCBT7 also 
induces the expression of most proteins, such as PFKFB4, CHOP, HIF1A and HMOX1, 
supporting their similar mechanisms (Figure V-5, 6). The signaling pathways affected by 
QCBT7 have a strong correlation with its proteasome inhibition activity.         
Overall, HK2, PFKFB4, CHOP, HIF1A, SESN2, TRXR1, NQO1, HMOX1 and 
SLC7A11 proteins are robustly upregulated in pancreatic cancer cells by QCBT7. Most proteins 
show a dose-dependent increase in response to QCBT7, MG132 and ixazomib. These results 
indicate that QCBT7 induces hypoxia, ER stress and glycolysis, and finally leads to cancer cell 
death, similar to MG132 and ixazomib 
PFKFB4 is a potential biomarker to study proteasome inhibition 
We identified that protein expression of PFKFB4 was significantly elevated by MG132, 
ixazomib and QCBT7. Additionally, QCBT7 increased PFKFB4 protein level back in the 
PFKFB4 knockdown MIA PaCa-2 cells (Figure V-S1). Our results show for the first time that 
PFKFB4 transcript and protein levels can be used to evaluate the response to proteasome 
inhibitors in pancreatic cancer. PFKFB4 is essential for cellular response to hypoxia, glucose 
metabolism and cell survival, and its depletion in p53-deficient prostate cancer cells inhibits 
tumor growth and cell survival 35,40-42. PFKFB4 is also recognized as an autophagy regulator, 
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relating to cancer cell death 43. Most importantly, it may be used as a new response regulatory 
protein to study the downstream signaling of MG132, ixazomib and other proteasome inhibitors.  
 
Figure V-S1. PFKFB4 protein level decreased by PFKFB4 siRNA at 30 pmol and 60 pmol, and QCBT7 increased 
the protein level back. The molecular weight of the target band is around 7 0kD. NC: scramble siRNA. 
 
Conclusions 
In this study, the STRING, GSEA and CMAP analyses of the novel compound QCBT7 
reveal that it induces transcriptional responses related to proteasome inhibition, hypoxia, ER 
stress and glycolysis. Moreover, QCBT7 blocked the degradation of ubiquitylated proteins, 
similar to MG132 and ixazomib. We demonstrated that PFKFB4, HK2, CHOP, HIF1A, SESN2, 
TRXR1, NQO1, HMOX1 and SLC7A11 protein levels increased upon QCBT7 treatment. 
MG132 and ixazomib also elevated PFKFB4, CHOP, HIF1A, SESN2, HMOX1 and SLC7A11 
protein levels. Additionally, for the first time we identify PFKFB4 as a potential biomarker to 
monitor proteasome inhibition. In conclusion, QCBT7 shares similarity with proteasome 
inhibitors at both the transcript and protein levels, and blocks the protein degradation pathway. 
Importantly, our study reveals and confirms the association between hypoxia, glycolysis, ER 
stress and proteasome inhibition in pancreatic cancer cells. 
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Methods 
Cell Culture. MIA PaCa-2, PANC-1, HCT 116 and KYSE-70 cells were cultured in RPMI 1640 
medium (Gibco) supplemented with 10% FBS (Atlanta Biologicals). Cells were grown at 37 °C 
in a humidified atmosphere of 5% CO2. All cell lines used were maintained in culture under 35 
passages and tested regularly for mycoplasma contamination using PlasmoTest Kit (InvivoGen, 
San Diego, CA). 
MTT assay. Cytotoxicity of compounds was determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay as previously described 44. Briefly, cells were seeded 
in 96-well tissue culture plates and treated with compounds or vehicle for 72 h after overnight 
attachment. 20 μL MTT (3 mg/mL) was added, and the cells were incubated with MTT for 3 h. 
DMSO was added after removing the media and absorbance was measured at 570 nm. 
Immunoblot. After overnight attachment in 6-well tissue culture plates, cells were treated with 
QCBT7 (3.3 μM or 6.6 μM), MG132 (3 μM), ixazomib (0.05 μM), or 2-CBA (3.3 μM or 6.6 
μM). After 24 h treatment, cells were washed with 1×DPBS and lysed using RIPA lysis buffer in 
the presence of 1×protease inhibitor cocktail (Sigma-Aldrich) and 1×phosphatase inhibitor 
cocktail (VWR International). Cell lysates were vortexed and centrifuged at 12,000×g for 15 min 
at 4 °C. Protein concentration of the samples was measured using a BCA protein assay (Thermo 
Fisher Scientific) and equal amounts of total proteins were resolved on 10% or 8% 
polyacrylamide via SDS-PAGE. The separated proteins were transferred onto PVDF membranes 
(Thermo Fisher Scientific, 0.45 μm) and blocked in 5% milk for 1 h at room temperature. The 
membranes were probed with primary antibodies in 5% milk or 5% BSA at 4 °C overnight with 
recommended dilution (HK2: Cell Signaling Technology (CST) #2106, PFKFB4: Thermo Fisher 
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PA5-15475, CHOP: CST #2895, HIF1A: CST #3716, SESN2: CST #8487, TRXR1: CST 
#15140, NQO1: CST #3187, HMOX1: CST #5061, SLC7A11: CST #12691, Ub: CST #3936). 
Secondary antibodies were added at 1:6000 dilution (Thermo Fisher Scientific, DyLight 800, 
#SA5-35571 and # SA5-35521) and membranes were incubated for 1 h at room temperature. 
Finally, membranes were imaged using Odyssey Imaging Systems (LI-COR Biosciences).  
PFKFB4 siRNA knock down study. siRNA targeting PFKFB4 was purchased from Thermo 
Fisher Scientific (#4427038). 8 million MIA PaCa-2 cells were seeded in 6-well tissue culture 
plates. After overnight attachment, 30 pmol and 60 pmol siPFKFB4 were added to MIA PaCa-2 
cells following the manufacturer’s protocol. QCBT7 (3.3 μM) was added to the cells at the same 
time. Cells were collected after 24 h treatment for later immunoblot. 
Bru-seq experiment and bioinformatics analysis. Bru-seq experiment for nascent RNA 
measurement was performed as previously reported 44. Briefly, MIA PaCa-2 cells were treated 
with QCBT7 for 4 h. Bromouridine was added to the cells at a final concentration of 2 mM in 
the last 30 min of the treatment. Cells were then collected in Trizol and total RNA was isolated. 
The bromouridine-containing RNA population was further isolated and sequenced. Sequencing 
reads were mapped to the hg19 reference genome. Further analysis was conducted using DESeq, 
GSEA，STRING and CMAP. R (version 3.3.2) was used to calculate Pearson correlation and 
make related figures.  
Statistics. Results were shown as mean ± standard deviation as stated in the figure or table 
legends. Unpaired t-test was performed for data analysis.  
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CHAPTER VI 
Concluding Summary and Future Directions 
In this dissertation, I report three novel scaffolds of small molecules that modulate 
cellular redox homeostasis and further characterize their MOAs in ferroptosis, mitochondrial 
functions, or proteasome inhibition, respectively. Specifically, in Chapter III, through lead 
optimization of a previously reported ROS inducer, we identified QD394 with higher 
hydrophilicity and a similar post-treatment transcriptomic profile to napabucasin. Both 
compounds inhibited the phosphorylation of STAT3, induced DNA damage, and altered redox 
signaling in pancreatic cancer cells. Combination with various cell death inhibitors revealed that 
QD394 stimulated an iron-, ROS-, and GPX4-mediated cell death. We also linked QD394 with 
the downregulation of LRPPRC and PNPT1, which are two mitochondrial proteins regulating 
RNA catabolic processes and negatively correlated to the overall survival of pancreatic cancer 
patients (Figure VI-1).  
                                     
Figure VI-1. Mechanistic studies of QD394 and QD394-Me in pancreatic cancer cells.  
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In Chapter IV, we demonstrated that the previously described ROS inducer, Mito-Chlor, 
repressed transcription of the mitochondrial genome. Examining Bru-seq profiles identified a 
novel quinone compound SQD1 with similar transcriptomic profiles to Mito-Chlor. Both 
compounds induced oxidative stress, hypoxic response, and activation of AP-1 transcription 
factors. Cumulatively, this study identified novel mitochondrial transcription inhibitors that also 
regulate redox signaling (Figure VI-2). 
 
Figure VI-2. Characterization of mitochondrial transcription inhibitors. 
 
In Chapter V, we identify a quinolin-chlorobenzothioate, QCBT7, as a new proteasome 
inhibitor showing cytotoxicity in a panel of cancer cell lines. QCBT7 caused an accumulation of 
ubiquitylated proteins in cancer cells and increased the expression of PFKFB4, CHOP, HMOX1, 
and SLC7A11 at both nascent RNA and protein levels. Overall, QCBT7 induces proteasome 
inhibition, hypoxic response, endoplasmic reticulum stress, and glycolysis. Furthermore, the 
involved signaling pathways emphasize the connection between redox signaling, hypoxia, and 
proteasome inhibition (Figure VI-3). 
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Figure VI-3. Characterization of QCBT7 analogs. 
In addition to the investigations of small molecules regulating ROS signaling, we also 
reviewed ROS-related genes in cancer. Briefly, in Chapter II, we used Bru-seq, progression, and 
survival analysis to evaluate how ROS-related genes are involved in disease progression and 
survival in pancreatic cancer. This study provides novel potential target genes or biomarkers for 
pancreatic cancer and helps elucidate the mechanism of ROS-inducing agents for drug 
development. Moreover, a machine learning model was built to predict drug synergism as shown 
in appendix, which also confirms the synergy between QD394 and napabucasin. 
 
Future directions 
Relationship between mitochondrial RNA and redox modulators 
We have observed that QD394 and QD394-Me decreased the protein expression of 
LRPPRC and PNPT1, and QD394 inhibited mitochondrial transcription in both heavy and light 
strands from Bru-seq analysis. These results suggest potential interactions between redox 
modulators and mitochondrial RNA for future investigation. Mitochondria are the major 
organelles as energy suppliers for cell growth and differentiation, and cancer cells reprogram the 
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metabolism of mitochondria to sustain aggressive proliferation and metastasis 1. This work 
provides a foundation to target mitochondrial RNA catabolism and transcription to treat cancer 
cells, and future work could determine whether LRPPRC and/or PNPT1 are the regulators of this 
mitochondrial transcription inhibition. LRPPRC is an essential protein to maintain the 
mitochondrial ultrastructure and stability of mitochondrial mRNAs, the deficiency of which 
could cause impairment of the electron transport chain and mitochondrial permeability 2,3. 
PNPT1 is involved in MT-ND6 transcript maturation and regulates mitochondrial RNA 
degradation and import 4–6. The further work may reveal the potential roles of LRPPRC and 
PNPT1 as drug targets to modulate mitochondria and cancer cell death. 
Moreover, we observed that NQO1, an ROS-related enzyme we discussed in Chapter I, 
may be involved in the downregulation of LRPPRC and PNPT1 by QD394 and QD394-Me. 
This indicated that NQO1 could mediate the decrease of mitochondrial proteins and transcripts, 
which requires further evaluations. QD394 and QD394-Me also displayed synergy with 
dicoumarol (an NQO1 inhibitor), yet we did not fully understand the underlying mechanisms. 
NQO1 is a well-known enzyme that either detoxifies or bioactivates quinones, and small 
molecules targeting NQO1 have been developed to show preclinical and clinical efficacy in 
cancer 7. Future work may improve the understanding of NQO1-modulated pathways related to 
mitochondrial proteins and RNAs, and disclose new MOAs of NQO1-targeting agents.   
In addition to determining RNA expression using Bru-seq, the effects on RNAs could 
also be evaluated via measuring RNA stability and degradation. There are established methods 
to determine RNA stability, including next-generation sequencing and biochemical and cell-
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based assays 8. Moreover, RNA-targeted therapies are widely used to treat diseases, and a future 
study could evaluate the potential role of redox modulators in RNA-based anticancer therapies. 
In vivo studies of redox modulators 
    We successfully improved the plasma stability and reduced the systemic toxicity of 
QD394 via structural optimization. However, the optimized analog QD394-Me still had a short 
half-life in vivo. It is possible that QD394-Me could bind to plasma protein or excrete rapidly in 
mice. Although QD394-Me had low plasma concentration, it still could be a promising 
anticancer candidate because three out of five mice showed a delay of tumor growth in the 
preliminary animal study. To further improve and confirm its in vivo efficacy, a new formulation 
or delivery system could be used to slow down compound metabolism in the plasma, such as 
using nanoparticles that could improve the PK profiles of compounds 9,10. Additionally, both 
immunodeficient and immunocompetent mouse models of pancreatic cancer will be necessary to 
evaluate the efficacy of our redox modulators, since different cancers may have different 
response rates to the same treatment. ROS inducers could sensitize multidrug resistance cancer 
cells to certain chemotherapeutic drugs 11, and we have observed synergistic effects between the 
redox modulators and FDA-approved drugs in vitro. Therefore, drug combination studies could 
also be tested to achieve better efficacy.  
GPX4-targeted drug design 
QD394-Me destabilized GPX4 in the CETSA experiments and its cytotoxicity was 
significantly dependent on GPX4, suggesting their potential interactions for further validation. 
GPX4 inhibition or depletion induces the accumulation of lipid peroxides and ferroptosis, and 
GPX4 inhibitors are more selective to cancer cells with a mesenchymal or drug-resistant 
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signature 12. The four major classes of ferroptosis inducers that we mentioned in Chapter II are 
all involved in regulating this central protein GPX4. Specifically, erastin indirectly suppresses 
GPX4 activity by decreasing GSH concentration; RSL3 directly reacts with the nucleophilic 
amino acid residues at the active site of GPX4 and reduces its activity; FIN56 promotes the 
degradation of GPX4; FINO2 indirectly inactivates GPX4 via unknown mechanisms 13. It is 
possible that QD394-Me has similar mechanisms to one or several of these known ferroptosis 
inducers. It would be necessary to evaluate the effect of QD394-Me on GPX4 activity and 
binding in future studies to confirm the target. To measure GPX4 activity, an LC-MS-based or 
HP-TLC-based GPX4 activity assay could be used 14. To prove the binding to GPX4, QD394-
Me could be synthesized with an affinity tag to pull down the protein targets, and proteomics 
could be further performed to identify the binding partners 14. This work may lead to a new class 
of GPX4-targeted small molecules to treat cancer, and the understanding of their binding 
mechanisms may assist design of novel GPX4 inhibitors as ferroptosis inducers.  
Connections with RIP1-related pathways   
RIP1-mediated pathways could be involved in MOAs of QD394 for further investigation. 
QD394 synergized with RIP1 kinase inhibitors (necrostatin-1 and nec-1s) and blocked the 
stabilization of RIP1 protein caused by necrostatin-1. However, the cytotoxicity of QD394 is not 
dependent on RIP1. We have not found the reasons for these effects, and it could be further 
explored to understand the relationships between ROS inducers and RIP1 signaling pathways. 
RIP1 works as a central switch between necroptosis and apoptosis, depending on the activity of 
caspase 8 15. When caspase 8 is active, cells will be driven to caspase-dependent apoptosis; when 
caspase 8 is inactive, RIP1 will not be cleaved and mobilize RIP3 to phosphorylate MLKL, 
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inducing necroptosis. Future studies may be able to determine how RIP1-related pathways and 
caspase 8 activity are related to the cytotoxicity of QD394. This may also suggest other cell 
death pathways of QD394, besides the ferroptosis we characterized in the dissertation. This 
future study may provide insights into the interconnections among complex cell death pathways 
in cancer. 
Altogether, this dissertation details the preclinical evaluation of novel small-molecule 
redox modulators in pancreatic cancer, and identifies novel ROS-related genes that are essential 
for cytotoxicity of redox modulators, PDAC progression, and patient survival. It improves the 
understanding of the relationship between redox signaling and cancer cell death, and provides 
the foundation of rational design of redox modulators. Future studies of redox modulators will 
seek to understand their deeper connections with mitochondrial transcription, GPX4 activity and 
binding, and RIP1-involved pathways. Systematic animal studies are needed to evaluate the in 
vivo efficacy of QD394-Me in pancreatic cancer. Additionally, novel ROS-related genes, such as 
NQO1 and ERO1, could be further explored in terms of their functional roles in pancreatic 
cancer based on our bioinformatics analysis. 
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APPENDIX 
Drug Synergism Prediction Using Machine Learning 
Single-agent therapies have reached their bottleneck due to drug resistance and genetic 
heterogeneity in complex diseases. Combination therapies become better options than 
monotherapies for many diseases, including cancer and HIV, since they can increase the efficacy 
and reduce the toxicity and side effects in patients 1–3. However, random combinations of drugs 
may cause adverse effects or lessen the efficacy. With the emergence of a large number of drugs 
and drug candidates, it is costly, time-consuming and labor-intensive to test every pair through in 
vitro drug screening experiments. Alternatively, computational tools such as machine learning 
techniques can predict the synergistic effects of drug pairs more efficiently and prioritize the 
combinations for experimental and clinical tests3. Therefore, it is essential to develop a fast and 
convenient model to accurately predict drug combination effects to approach the experimental 
results. 
Many efforts have been made to predict drug synergy in cancer, utilizing Random 
Forests, Naive Bayes and deep learning algorithms. These pioneering studies have provided 
great advancement to estimate drug synergy 4–6. To further facilitate the research of drug synergy, 
the Dialogue on Reverse Engineering Assessment and Method (DREAM) 7 organized the 
AstraZeneca-Sanger Drug Combination Prediction Challenge 8 to systematically evaluate the 
performance of different methods using a large dataset consisting of 11,500 experimentally 
Notes: This work has been published as Li, H., Hu, S., Neamati, N. & Guan, Y. Bioinformatics 35, 2338–
2339 (2019). 
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tested synergy scores of 118 drugs in 85 cancer cell lines. Our prediction algorithm ranked first 
in this challenge, leveraging the information from pharmacological data, molecular data and the 
gene-gene interaction network. Here, we present the software, TAIJI, to predict drug synergy 
based on our winning algorithm. 
Methods and results 
TAIJI is a novel program that utilizes both the pharmacological monotherapy results and 
cell line-specific molecular profiles (Appendix-1). Specifically, multiple features are extracted 
from the dose-response curves and the metrics of treatment effects. In addition, the post-
treatment molecular features are simulated based on the pre-treatment genomic profiles and the 
gene-gene interaction network 9 via a network propagation approach. The nonlinear interactions 
between chemical features are learned by the random forest regressor 10–12. Meanwhile, TAIJI is 
developed in the context of the largest dataset in the AstraZeneca-Sanger DREAM drug 
combination challenge, covering drug combination experiments in a broad spectrum of 85 
cancer cell lines across different cancer tissues (Appendix-2A). To accelerate the computation, 
monotherapy- and molecular-based models in TAIJI are pre-trained, and the prediction of a drug 
pair can be finished within one second on average (Appendix -2B). Of note, TAIJI is a robust 
model by integrating the cross-drug and cross-cell line information. The average Pearson’s 
correlation between predictions and observations is 0.53 (Appendix-2C), approaching the 
experimental replicates-level accuracy, the correlation of which is 0.56 13. TAIJI is implemented 
using Perl and Python, two commonly used programming languages. It only requires scikit-learn, 
a popular machine learning package in Python. 
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Appendix-1. The workflow of TAIJI framework. (A) TAIJI captures multiple informative features from 1) the dose-
response curve 2) the frequency of observed drugs and cell lines 3) cell line-specific genomic profiles. (B) A 
random forest regressor is used as the base learner, with a total of 300 trees and a maximum tree depth of 3. (C) 
TAIJI predicts the synergy of drug 1 - drug 2 - cell line combinations. 
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Appendix-2. Runtimes and prediction performance of TAIJI. (A) TAIJI is trained on a large drug synergy dataset 
covering 8 tissue subtypes containing 85 cancer cell lines (B) The runtimes for TAIJI using different numbers of 
cell line - drug 1 - drug 2 combinations. A total of 100, 200, 500, 800 and 1000 combinations were randomly 
selected for testing. Notably, the main time-consuming step is calculating the post-treatment molecular profile of a 
drug pair so that the runtime is not linear with the number of combinations. When a drug pair is tested across 
multiple cell lines, the runtime per combination becomes small. (C) The distribution of tissue-specific prediction 
correlations. The dashed line corresponds to the average upper limit of correlations calculated from technical 
replicates. 
Conclusions 
In this study, we present TAIJI, a novel fast software to predict drug synergy using the 
state-of-the-art machine learning algorithm. This software can be downloaded and easily used by 
computational biologists and pharmacologists to estimate the drug combinatorial effects and 
guide experimental and clinical trial design. This software predicts a synergistic effect between 
QD394 and napabucasin with a positive score, which is consistent with our experimental results 
in Chapter III. 
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